APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 3
March 2012



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

32nd EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2012

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

32nd EDITION

Cumulative Supplement 3

March 2012

CONTENTS

PAGE

1.0 INTRODUCTION iii
1.1 How to use the Cumulative Supplement iii
1.2 Cumulative Supplement Content iv
1.3 Applicant Name Changes v
1.4 Levothyroxine Sodium v
1.5 Availability of the Edition vi
1.6 Report of Counts for the Prescription Drug Product List vii
1.7 Cumulative Supplement Legend viii

DRUG PRODUCT LISTS
Prescription Drug Product List 1-1
OTC Drug Product List 2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List 3-1
Orphan Product Designations and Approvals List 4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution 5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM
A. Patent and Exclusivity Lists A-1
B. Patent and Exclusivity Terms B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

32nd EDITION

CUMULATIVE SUPPLEMENT 3
March 2012

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ALCON UNIVERSAL LTD (ALCON UNIVERSAL)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
OVATION PHARMACEUTICALS INC (OVATION PHARMS)	OAK PHARMACEUTICALS INC (OAK PHARMS)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752)tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use

in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2011	MAR 2012	JUN 2012	SEPT 2012	DEC 2012
DRUG PRODUCTS LISTED	14480	14711			
SINGLE SOURCE	2451 (16.9%)	2446 (16.6%)			
MULTISOURCE	11953 (82.5%)	12187 (82.8%)			
THERAPEUTICALLY EQUIVALENT	11792 (81.4%)	12037 (81.8%)			
NOT THERAPEUTICALLY EQUIVALENT	161 (1.1%)	150 (1.0%)			
EXCEPTIONS[1]	76 (0.5%)	78 (0.5%)			
NEW MOLECULAR ENTITIES APPROVED	6	8			
NUMBER OF APPLICANTS	810	826			

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACARBOSE

TABLET; ORAL
ACARBOSE

AB		EMCURE PHARMS LTD	25MG	A202271	001	Feb 07, 2012	Jan	NEWA
AB			50MG	A202271	002	Feb 07, 2012	Jan	NEWA
AB			100MG	A202271	003	Feb 07, 2012	Jan	NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	+	PHARM ASSOC	120MG/5ML;12MG/5ML	A087508	001		Jan	CRLD

SUSPENSION; ORAL
CAPITAL AND CODEINE

	+	VALEANT	120MG/5ML;12MG/5ML	A086024	001		Jan	CTEC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		VISTAPHARM	325MG/15ML;7.5MG/15ML	A200343	001	Jan 25, 2012	Jan	NEWA

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>A>	AA	AUROLIFE PHARMA LLC	325MG;5MG	A201013	001	Apr 11, 2012	Mar	NEWA
>A>	AA		325MG;7.5MG	A201013	002	Apr 11, 2012	Mar	NEWA
>A>	AA		325MG;10MG	A201013	003	Apr 11, 2012	Mar	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

>A>	AA	ACTAVIS TOTOWA	325MG;7.5MG	A040800	001	Apr 03, 2012	Mar	NEWA
>A>	AA		325MG;10MG	A040800	002	Apr 03, 2012	Mar	NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

>A>	AB	ALVOGEN INC	325MG;37.5MG	A202076	001	Mar 30, 2012	Mar	NEWA

ADAPALENE

CREAM; TOPICAL
ADAPALENE

AB		FOUGERA PHARMS	0.1%	A090824	001	Jun 30, 2010	Jan	CAHN

ADENOSINE

INJECTABLE; INJECTION
ADENOSINE

>D>	AP	TEVA PARENTERAL	3MG/ML	A078676	001	Jul 31, 2008	Mar	DISC
>A>		@	3MG/ML	A078676	001	Jul 31, 2008	Mar	DISC
		@	3MG/ML	A076564	001	Jun 16, 2004	Jan	DISC

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL
ALCLOMETASONE DIPROPIONATE

AB		FOUGERA PHARMS	0.05%	A076973	001	Jul 12, 2005	Jan	CAHN

OINTMENT; TOPICAL
ALCLOMETASONE DIPROPIONATE

	AB	FOUGERA PHARMS	0.05%	A076884	001	Jul 18, 2005	Jan	CAHN

ALENDRONATE SODIUM

TABLET, EFFERVESCENT; ORAL
BINOSTO

>A>	+	MISSION PHARMA	EQ 70MG BASE	N202344	001	Mar 12, 2012	Mar	NEWA

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALFUZOSIN HYDROCHLORIDE

	AB	INVAGEN PHARMS	10MG	A090284	001	Jan 17, 2012	Jan	NEWA

ALGLUCERASE

INJECTABLE; INJECTION
CEREDASE

>D>	+	GENZYME	80 UNITS/ML	N020057	003	Apr 05, 1991	Mar	DISC
>A>	@		80 UNITS/ML	N020057	003	Apr 05, 1991	Mar	DISC

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

>D>	AB	SANDOZ	0.5MG	A077777	001	Jun 30, 2006	Mar	DISC
>D>	AB		1MG	A077777	002	Jun 30, 2006	Mar	DISC
>D>	AB		2MG	A077777	003	Jun 30, 2006	Mar	DISC
>D>	AB		3MG	A077777	004	Jun 30, 2006	Mar	DISC
>A>	@	SANDOZ INC	0.5MG	A077777	001	Jun 30, 2006	Mar	DISC
>A>	@		1MG	A077777	002	Jun 30, 2006	Mar	DISC
>A>	@		2MG	A077777	003	Jun 30, 2006	Mar	DISC
>A>	@		3MG	A077777	004	Jun 30, 2006	Mar	DISC

TABLET, ORALLY DISINTEGRATING; ORAL
NIRAVAM

	AB	UCB INC	0.25MG	N021726	001	Jan 19, 2005	Jan	CAHN
	AB		0.5MG	N021726	002	Jan 19, 2005	Jan	CAHN
	AB	+	1MG	N021726	003	Jan 19, 2005	Jan	CAHN
	AB		2MG	N021726	004	Jan 19, 2005	Jan	CAHN

ALVIMOPAN

CAPSULE; ORAL
ENTEREG

	+	CUBIST PHARMS	12MG	N021775	001	May 20, 2008	Feb	CAHN

AMCINONIDE

CREAM; TOPICAL
AMCINONIDE

	AB	+ FOUGERA PHARMS	0.1%	A076065	001	May 15, 2003	Jan	CAHN

LOTION; TOPICAL
AMCINONIDE

	+	FOUGERA PHARMS	0.1%	A076329	001	Nov 06, 2002	Jan	CAHN

OINTMENT; TOPICAL
AMCINONIDE

	AB	+ FOUGERA PHARMS	0.1%	A076096	001	Nov 19, 2002	Jan	CAHN

AMINO ACIDS

INJECTABLE; INJECTION

>A>			AMINO ACIDS						
>A>			B BRAUN	15%(150GM/1000ML)	A091112	001	Apr 13, 2012	Mar	NEWA
>A>				15%(300GM/2000ML)	A091112	002	Apr 13, 2012	Mar	NEWA
			NOVAMINE 15%						
>D>			@ HOSPIRA INC	15% (75GM/500ML)	N017957	004	Nov 28, 1986	Mar	CPOT
>A>			@	15% (75GM/500ML)	N017957	004	Nov 28, 1986	Mar	CPOT

AMINOCAPROIC ACID

INJECTABLE; INJECTION

			AMICAR						
>A>			@ CLOVER PHARMS	250MG/ML	N015229	002		Mar	CAHN
>D>			@ XANODYNE PHARM	250MG/ML	N015229	002		Mar	CAHN

SYRUP; ORAL

			AMICAR						
>A>	AA	+	CLOVER PHARMS	1.25GM/5ML	N015230	002		Mar	CAHN
>D>	AA	+	XANODYNE PHARM	1.25GM/5ML	N015230	002		Mar	CAHN

TABLET; ORAL

			AMICAR						
>A>	AB		CLOVER PHARMS	500MG	N015197	001		Mar	CAHN
>A>		+		1GM	N015197	002	Jun 24, 2004	Mar	CAHN
>D>	AB		XANODYNE PHARM	500MG	N015197	001		Mar	CAHN
>D>		+		1GM	N015197	002	Jun 24, 2004	Mar	CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

			AMIODARONE HYDROCHLORIDE						
			@ TEVA PARENTERAL	50MG/ML	A076163	001	Sep 05, 2003	Jan	DISC

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

			CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE						
			MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986	Feb	CTEC
		+		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986	Feb	CRLD
			LIMBITROL						
			@ VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949	001		Feb	DISC
			LIMBITROL DS						
			@ VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949	002		Feb	DISC

AMLODIPINE BESYLATE

TABLET; ORAL

			AMLODIPINE BESYLATE						
>A>	AB		MACLEODS PHARMS LTD	EQ 5MG BASE	A201380	001	Apr 13, 2012	Mar	NEWA
>A>	AB			EQ 10MG BASE	A201380	002	Apr 13, 2012	Mar	NEWA

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

			PREVPAC						
>A>		+	TAKEDA PHARMS USA	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	N050757	001	Dec 02, 1997	Mar	CAHN

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS; ORAL

			PREVPAC						
>D>		+	TAKEDA PHARMS NA	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	N050757	001	Dec 02, 1997	Mar	CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		AUROBINDO PHARMA LTD	250MG;EQ 125MG BASE	A091569	001	Jan 20, 2012	Jan	NEWA
AB			500MG;EQ 125MG BASE	A091569	002	Jan 20, 2012	Jan	NEWA
AB			875MG;EQ 125MG BASE	A091568	001	Jan 20, 2012	Jan	NEWA

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB		SHIRE LLC	EQ 0.5MG BASE	N020333	001	Mar 14, 1997	Jan	CAHN

ANAGRELIDE HYDROCHLORIDE

>D> AB		SANDOZ	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Mar	DISC
>D> AB			EQ 1MG BASE	A076683	002	Apr 18, 2005	Mar	DISC
>A>	@	SANDOZ INC	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Mar	DISC
>A>	@		EQ 1MG BASE	A076683	002	Apr 18, 2005	Mar	DISC

ARGATROBAN

INJECTABLE; INJECTION

ACOVA

AP	+	PFIZER	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	Jan	CTNA

ARGATROBAN

AP		HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049	001	Jan 05, 2012	Jan	NEWA

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

AA		NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9MG;2.691GM ;7.5GM	A090145	001	Jan 25, 2012	Jan	NEWA

MOVIPREP

AA	+	SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM ;7.5GM	N021881	001	Aug 02, 2006	Jan	CFTG

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB		PROSAM LABS	325MG;200MG	A040252	001	Dec 10, 1997	Feb	CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Feb	CAHN

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	+	BEDFORD	10MG/ML	A074901	001	Jul 18, 1997	Feb	CTEC
AP		SAGENT PHARMS	10MG/ML	A091489	001	Feb 17, 2012	Feb	NEWA

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP	+	BEDFORD	10MG/ML	A074900	001	Jul 18, 1997	Feb	CTEC
AP		SAGENT PHARMS	10MG/ML	A091488	001	Feb 17, 2012	Feb	NEWA

AXITINIB

TABLET; ORAL
INLYTA

	PFIZER	1MG	N202324	001	Jan 27, 2012	Jan	NEWA
+		5MG	N202324	002	Jan 27, 2012	Jan	NEWA

BACLOFEN

TABLET; ORAL
BACLOFEN

AB	PROSAM LABS	10MG	A077089	001	Oct 31, 2007	Feb	CAHN
AB		20MG	A077088	001	Oct 31, 2007	Feb	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
KEMSTRO

	@ UCB INC	10MG	N021589	001	Oct 30, 2003	Jan	CAHN
	@	20MG	N021589	002	Oct 30, 2003	Jan	CAHN

BALSALAZIDE DISODIUM

TABLET; ORAL
GIAZO

+	SALIX PHARMS	1.1GM	N022205	001	Feb 03, 2012	Feb	NEWA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; NASAL
QNASL

>A>	+	TEVA BRANDED PHARM	0.08MG/ACTIVATION	N202813	001	Mar 23, 2012	Mar	NEWA

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL
BENZAMYCIN

AB	+	VALEANT INTL	5%;3%	N050557	001	Oct 26, 1984	Jan	CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL
BENZPHETAMINE HYDROCHLORIDE

AA	EMCURE PHARMS LTD	50MG	A202061	001	Jan 27, 2012	Jan	NEWA

BENZTROPINE MESYLATE

INJECTABLE; INJECTION
COGENTIN

AP	+	OAK PHARMS AKORN	1MG/ML	N012015	001		Feb	CAHN

TABLET; ORAL
BENZTROPINE MESYLATE

	@ LANNETT HOLDINGS INC	0.5MG	A088877	001	Apr 11, 1985	Jan	DISC
	@	1MG	A088894	001	Apr 11, 1985	Jan	DISC
	@	2MG	A088895	001	Apr 11, 1985	Jan	DISC
AA	PROSAM LABS	0.5MG	A040699	001	Feb 14, 2008	Feb	CMFD
AA		1MG	A040705	001	Feb 14, 2008	Feb	CMFD
AA		2MG	A040706	001	Feb 14, 2008	Feb	CMFD
AA	+ USL PHARMA	0.5MG	A040103	001	Dec 12, 1996	Jan	CRLD
AA	+	1MG	A040103	002	Dec 12, 1996	Jan	CRLD
AA	+	2MG	A040103	003	Dec 12, 1996	Jan	CRLD

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL
BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	N019137	001	Jun 26, 1984	Jan	CAHN

CREAM, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A076215	001	Dec 09, 2003	Jan	CAHN

GEL, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	A075276	001	May 13, 2003	Jan	CAHN

LOTION, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A077111	001	May 21, 2007	Jan	CAHN

OINTMENT, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A075373	001	Jun 22, 1999	Jan	CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A075502	001	Jun 05, 2001	Jan	CAHN

LOTION; TOPICAL
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A076516	001	Jun 16, 2005	Jan	CAHN

LOTRISONE

AB	+	SCHERING CORP	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Feb	CAHN

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL
LUXIQ

	+	STIEFEL	EQ 0.12% BASE	N020934	001	Feb 28, 1999	Jan	CAHN

BISOPROLOL FUMARATE

TABLET; ORAL
ZEBETA

AB		TEVA WOMENS	5MG	N019982	002	Jul 31, 1992	Jan	CAHN
AB	+		10MG	N019982	001	Jul 31, 1992	Jan	CAHN

BOCEPREVIR

CAPSULE; ORAL
VICTRELIS

>A>	+	MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011	Mar	CAHN
>D>	+	SCHERING	200MG	N202258	001	May 13, 2011	Mar	CAHN

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS
VELCADE

	+	MILLENNIUM PHARMS	3.5MG/VIAL	N021602	001	May 13, 2003	Jan	CDFR

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION
SYMBICORT

	+	ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006	Jan	CDFR
	+		0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006	Jan	CDFR

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FORFIVO XL

>A>		+	EDGEMONT PHARMS LLC	450MG	N022497	001	Nov 10, 2011	Mar	CAHN
>D>		+	INTELGENX CORP	450MG	N022497	001	Nov 10, 2011	Mar	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

>D>	AB		APOTEX	5MG	A075521	001	Apr 05, 2002	Mar	DISC
>A>			@	5MG	A075521	001	Apr 05, 2002	Mar	DISC
>D>	AB			10MG	A075521	002	Apr 05, 2002	Mar	DISC
>A>			@	10MG	A075521	002	Apr 05, 2002	Mar	DISC
>D>	AB			15MG	A075521	003	Apr 05, 2002	Mar	DISC
>A>			@	15MG	A075521	003	Apr 05, 2002	Mar	DISC
>D>	AB		EGIS	5MG	A075119	001	Mar 14, 2002	Mar	DISC
>A>			@	5MG	A075119	001	Mar 14, 2002	Mar	DISC
>D>	AB			10MG	A075119	002	Mar 14, 2002	Mar	DISC
>A>			@	10MG	A075119	002	Mar 14, 2002	Mar	DISC
>D>	AB			15MG	A075119	003	Jan 23, 2003	Mar	DISC
>A>			@	15MG	A075119	003	Jan 23, 2003	Mar	DISC
>D>	AB		PROSAM LABS	5MG	A075388	001	May 09, 2002	Mar	DISC
>A>			@	5MG	A075388	001	May 09, 2002	Mar	DISC
	AB			5MG	A075388	001	May 09, 2002	Feb	CMFD
>D>	AB			10MG	A075388	002	May 09, 2002	Mar	DISC
>A>			@	10MG	A075388	002	May 09, 2002	Mar	DISC
	AB			10MG	A075388	002	May 09, 2002	Feb	CMFD
>D>	AB			15MG	A075388	003	May 09, 2002	Mar	DISC
>A>			@	15MG	A075388	003	May 09, 2002	Mar	DISC
	AB			15MG	A075388	003	May 09, 2002	Feb	CMFD
	AB			30MG	A078302	001	Dec 17, 2007	Feb	CMFD

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

	AP	+	BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Jan	CAHN

SOLUTION; ORAL

CAFCIT

	AA	+	BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Jan	CAHN

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

	AT		FOUGERA PHARMS	0.005%	A078305	001	May 06, 2008	Jan	CAHN

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL

PARCOPA

	AB		UCB INC	10MG;100MG	A076699	001	Aug 27, 2004	Jan	CAHN
	AB			25MG;100MG	A076699	002	Aug 27, 2004	Jan	CAHN
	AB	+		25MG;250MG	A076699	003	Aug 27, 2004	Jan	CAHN

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

>A>	AP	CIPLA LTD	50MG/VIAL	A077383	001	Jan 27, 2006	Mar	CAHN
>A>	AP		150MG/VIAL	A077383	002	Jan 27, 2006	Mar	CAHN
>A>	AP		450MG/VIAL	A077383	003	Jan 27, 2006	Mar	CAHN
>D>	AP	WATSON LABS	50MG/VIAL	A077383	001	Jan 27, 2006	Mar	CAHN
>D>	AP		150MG/VIAL	A077383	002	Jan 27, 2006	Mar	CAHN
>D>	AP		450MG/VIAL	A077383	003	Jan 27, 2006	Mar	CAHN

PARAPLATIN

		@ CORDEN PHARMA	50MG/VIAL	N019880	001	Mar 03, 1989	Feb	CAHN
		@	150MG/VIAL	N019880	002	Mar 03, 1989	Feb	CAHN
		@	450MG/VIAL	N019880	003	Mar 03, 1989	Feb	CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

	AP	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Jan	NEWA
	AP		150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Jan	NEWA
	AP		450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Jan	NEWA
	AP		600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Jan	NEWA
>A>	AP	CIPLA LTD	50MG/5ML (10MG/ML)	A077861	001	Jan 18, 2007	Mar	CAHN
>A>	AP		150MG/15ML (10MG/ML)	A077861	002	Jan 18, 2007	Mar	CAHN
>A>	AP		450MG/45ML (10MG/ML)	A077861	003	Jan 18, 2007	Mar	CAHN
>A>	AP		600MG/60ML (10MG/ML)	A077861	004	Jan 18, 2007	Mar	CAHN
>D>	AP	WATSON LABS	50MG/5ML (10MG/ML)	A077861	001	Jan 18, 2007	Mar	CAHN
>D>	AP		150MG/15ML (10MG/ML)	A077861	002	Jan 18, 2007	Mar	CAHN
>D>	AP		450MG/45ML (10MG/ML)	A077861	003	Jan 18, 2007	Mar	CAHN
>D>	AP		600MG/60ML (10MG/ML)	A077861	004	Jan 18, 2007	Mar	CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

	AA	PROSAM LABS	350MG	A040188	001	Mar 07, 1997	Feb	CAHN

CEFACLOR

FOR SUSPENSION; ORAL

CEFACLOR

	AB	+ RANBAXY	EQ 125MG BASE/5ML	A064166	001	Oct 02, 1997	Feb	CTEC
	AB	+	EQ 187MG BASE/5ML	A064165	001	Oct 02, 1997	Feb	CTEC
	AB	+	EQ 250MG BASE/5ML	A064164	001	Oct 02, 1997	Feb	CTEC
	AB	+	EQ 375MG BASE/5ML	A064155	001	Oct 02, 1997	Feb	CTEC
	AB	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412	001	Feb 17, 2012	Feb	NEWA
	AB		EQ 187MG BASE/5ML	A065412	002	Feb 17, 2012	Feb	NEWA
	AB		EQ 250MG BASE/5ML	A065412	003	Feb 17, 2012	Feb	NEWA
	AB		EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012	Feb	NEWA

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

>D>		CORNERSTONE THERAP	200MG	N021222	001	Aug 29, 2001	Mar	CAHN
>D>	+		400MG	N021222	002	Jul 21, 2008	Mar	CAHN
>A>		VANSEN PHARMA	200MG	N021222	001	Aug 29, 2001	Mar	CAHN
>A>	+		400MG	N021222	002	Jul 21, 2008	Mar	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CLAFORAN

>D>	AP		SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659	001	Jan 13, 1987	Mar	CRLD
>A>	AP	+		EQ 1GM BASE/VIAL	A062659	001	Jan 13, 1987	Mar	CRLD
>D>	AP			EQ 2GM BASE/VIAL	A062659	002	Jan 13, 1987	Mar	CRLD
>A>	AP	+		EQ 2GM BASE/VIAL	A062659	002	Jan 13, 1987	Mar	CRLD

CEFPROZIL

FOR SUSPENSION; ORAL
CEFPROZIL

	AB		APOTEX INC	125MG/5ML	A065351	001	Feb 29, 2012	Feb	NEWA
	AB			250MG/5ML	A065351	002	Feb 29, 2012	Feb	NEWA

TABLET; ORAL
CEFZIL

		@	CORDEN PHARMA	250MG	N050664	001	Dec 23, 1991	Feb	CAHN
		@		500MG	N050664	002	Dec 23, 1991	Feb	CAHN

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
CEFTRIAXONE

>D>	AP		SANDOZ	EQ 1GM BASE/VIAL	A065204	001	May 03, 2005	Mar	CRLD
>D>	AP			EQ 2GM BASE/VIAL	A065204	002	May 03, 2005	Mar	CRLD
>A>	AP	+	SANDOZ INC	EQ 1GM BASE/VIAL	A065204	001	May 03, 2005	Mar	CRLD
>A>	AP	+		EQ 2GM BASE/VIAL	A065204	002	May 03, 2005	Mar	CRLD

CICLESONIDE

AEROSOL, METERED; NASAL
ZETONNA

		+	NYCOMED GMBH	0.037MG/INH	N202129	001	Jan 20, 2012	Jan	NEWA

CICLOPIROX

CREAM; TOPICAL
CICLOPIROX

	AB		FOUGERA PHARMS	0.77%	A076435	001	Dec 29, 2004	Jan	CAHN

GEL; TOPICAL
CICLOPIROX

	AB		FOUGERA PHARMS	0.77%	A077896	001	Jun 10, 2008	Jan	CAHN
	AB		GLENMARK GENERICS	0.77%	A091595	001	Feb 29, 2012	Feb	NEWA

SHAMPOO; TOPICAL
CICLOPIROX

	AT		FOUGERA PHARMS	1%	A090146	001	May 25, 2010	Jan	CAHN

SOLUTION; TOPICAL
CICLOPIROX

	AT		MYLAN PHARMS INC	8%	A078567	001	Sep 18, 2007	Feb	CAHN

SUSPENSION; TOPICAL
CICLOPIROX

	AB		FOUGERA PHARMS	0.77%	A076422	001	Aug 06, 2004	Jan	CAHN

CIPROFLOXACIN

INJECTABLE; INJECTION
CIPROFLOXACIN

>D>	AP		TEVA PARENTERAL	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006	Mar	DISC
>A>		@		200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006	Mar	DISC
		@		400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006	Jan	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL
CIPROFLOXACIN HYDROCHLORIDE

		@ PLIVA	EQ 100MG BASE	A076426	001	Jun 15, 2005	Jan	DISC
		@	EQ 250MG BASE	A076426	002	Jun 15, 2005	Jan	DISC
		@	EQ 500MG BASE	A076426	003	Jun 15, 2005	Jan	DISC
		@	EQ 750MG BASE	A076426	004	Jun 15, 2005	Jan	DISC

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION
CISATRACURIUM BESYLATE

	AP	SANDOZ INC	EQ 2MG BASE/ML	A200159	001	Feb 03, 2012	Jan	NEWA

CISATRACURIUM BESYLATE PRESERVATIVE FREE

	AP	SANDOZ INC	EQ 2MG BASE/ML	A200154	001	Feb 03, 2012	Jan	NEWA
	AP		EQ 10MG BASE/ML	A200154	002	Feb 03, 2012	Jan	NEWA

NIMBEX

	AP +	ABBOTT	EQ 2MG BASE/ML	N020551	001	Dec 15, 1995	Jan	CFTG

NIMBEX PRESERVATIVE FREE

	AP +	ABBOTT	EQ 2MG BASE/ML	N020551	003	Dec 15, 1995	Jan	CFTG
	AP +		EQ 10MG BASE/ML	N020551	002	Dec 15, 1995	Jan	CFTG

CISPLATIN

INJECTABLE; INJECTION
CISPLATIN

>D>	AP	TEVA PARENTERAL	1MG/ML	A074814	001	May 16, 2000	Mar	DISC
>A>		@	1MG/ML	A074814	001	May 16, 2000	Mar	DISC

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL
CLINDAMYCIN PHOSPHATE

	AB	FOUGERA PHARMS	EQ 2% BASE	A065139	001	Dec 27, 2004	Jan	CAHN

GEL; TOPICAL
CLINDAMYCIN PHOSPHATE

	AB	FOUGERA PHARMS	EQ 1% BASE	A064160	001	Jan 28, 2000	Jan	CAHN

LOTION; TOPICAL
CLINDAMYCIN PHOSPHATE

	AB	FOUGERA PHARMS	EQ 1% BASE	A065067	001	Jan 31, 2002	Jan	CAHN

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

	AT	FOUGERA PHARMS	EQ 1% BASE	A065254	001	Feb 14, 2006	Jan	CAHN

CLOBAZAM

TABLET; ORAL
ONFI

>D>		LUNDBECK INC	5MG	N202067	001	Oct 21, 2011	Mar	CAHN
>D>			10MG	N202067	002	Oct 21, 2011	Mar	CAHN
>D>	+		20MG	N202067	003	Oct 21, 2011	Mar	CAHN
>A>		LUNDBECK LLC	5MG	N202067	001	Oct 21, 2011	Mar	CAHN
>A>			10MG	N202067	002	Oct 21, 2011	Mar	CAHN
>A>	+		20MG	N202067	003	Oct 21, 2011	Mar	CAHN

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CLOBETASOL PROPIONATE (EMOLLIENT)

	AB2	FOUGERA PHARMS	0.05%	A075430	001	May 26, 1999	Jan	CAHN

		CREAM; TOPICAL							
		TEMOVATE							
	AB1	+ FOUGERA PHARMS	0.05%	N019322	001	Dec 27, 1985	Jan	CAHN	
		GEL; TOPICAL							
		CLOBETASOL PROPIONATE							
	AB	FOUGERA PHARMS	0.05%	A075368	001	Feb 15, 2000	Jan	CAHN	
		TEMOVATE							
	AB	+ FOUGERA PHARMS	0.05%	N020337	001	Apr 29, 1994	Jan	CAHN	
		OINTMENT; TOPICAL							
		CLOBETASOL PROPIONATE							
	AB	FOUGERA PHARMS	0.05%	A074407	001	Feb 23, 1996	Jan	CAHN	
		TEMOVATE							
	AB	+ FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Jan	CAHN	
		SOLUTION; TOPICAL							
		CLOBETASOL PROPIONATE							
	AT	FOUGERA PHARMS	0.05%	A075391	001	Feb 08, 1999	Jan	CAHN	
		TEMOVATE							
	AT	+ FOUGERA PHARMS	0.05%	N019966	001	Feb 22, 1990	Jan	CAHN	
		CLONIDINE HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		DURACLON							
	AP	MYLAN INSTITUTIONAL	1 MG/10 ML (0.1 MG/ML)	N020615	001	Oct 02, 1996	Feb	CAHN	
	AP	+	5 MG/10 ML (0.5 MG/ML)	N020615	002	Apr 27, 1999	Feb	CAHN	
		CLOPIDOGREL BISULFATE							
		TABLET; ORAL							
		CLOPIDOGREL BISULFATE							
>D>		@ DR REDDYS LABS INC	EQ 75MG BASE	A076273	001	Jan 14, 2008	Mar	CMFD	
>A>	AB		EQ 75MG BASE	A076273	001	Jan 14, 2008	Mar	CMFD	
		PLAVIX							
>D>		SANOFI AVENTIS US	EQ 75MG BASE	N020839	001	Nov 17, 1997	Mar	CTEC	
>A>	AB		EQ 75MG BASE	N020839	001	Nov 17, 1997	Mar	CTEC	
		CLORAZEPATE DIPOTASSIUM							
		CAPSULE; ORAL							
		TRANXENE							
>D>		@ LUNDBECK INC	3.75MG	N017105	001		Mar	CAHN	
>D>		@	7.5MG	N017105	002		Mar	CAHN	
>D>		@	15MG	N017105	003		Mar	CAHN	
>A>		@ LUNDBECK LLC	3.75MG	N017105	001		Mar	CAHN	
>A>		@	7.5MG	N017105	002		Mar	CAHN	
>A>		@	15MG	N017105	003		Mar	CAHN	
		TABLET; ORAL							
		TRANXENE							
>D>	AB	LUNDBECK INC	3.75MG	N017105	006		Mar	CAHN	
>D>	AB		7.5MG	N017105	007		Mar	CAHN	
>D>	AB	+	15MG	N017105	008		Mar	CAHN	
>A>	AB	LUNDBECK LLC	3.75MG	N017105	006		Mar	CAHN	
>A>	AB		7.5MG	N017105	007		Mar	CAHN	
>A>	AB	+	15MG	N017105	008		Mar	CAHN	
		TRANXENE SD							
>D>		@ LUNDBECK INC	11.25MG	N017105	005		Mar	CAHN	
>D>		@	22.5MG	N017105	004		Mar	CAHN	
>A>		@ LUNDBECK LLC	11.25MG	N017105	005		Mar	CAHN	
>A>		@	22.5MG	N017105	004		Mar	CAHN	

CLOTRIMAZOLE

CREAM; TOPICAL
CLOTRIMAZOLE

	AB		FOUGERA PHARMS	1%	A078338	001	Sep 02, 2008	Jan	CAHN

CROMOLYN SODIUM

CONCENTRATE; ORAL
GASTROCROM

>D>	AA	+	AZUR PHARMA	100MG/5ML	N020479	001	Feb 29, 1996	Mar	CAHN
>A>	AA	+	JAZZ PHARMS COMMERCL	100MG/5ML	N020479	001	Feb 29, 1996	Mar	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

	AB		PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Feb	CAHN
	AB			10MG	A077209	001	Oct 04, 2005	Feb	CAHN

CYTARABINE

INJECTABLE; INJECTION
CYTARABINE

	AP		ONCO THERAPIES LTD	100MG/ML	A201784	001	Jan 30, 2012	Jan	NEWA

DACTINOMYCIN

INJECTABLE; INJECTION
COSMEGEN

>D>	AP	+	LUNDBECK INC	0.5MG/VIAL	N050682	001		Mar	CAHN
>A>	AP	+	LUNDBECK LLC	0.5MG/VIAL	N050682	001		Mar	CAHN

DARUNAVIR ETHANOLATE

SUSPENSION; ORAL
PREZISTA

		+	JANSSEN PRODS	EQ 100MG BASE/ML	N202895	001	Dec 16, 2011	Feb	CAHN

TABLET; ORAL
PREZISTA

			JANSSEN PRODS	EQ 75MG BASE	N021976	004	Dec 18, 2008	Feb	CAHN
				EQ 150MG BASE	N021976	005	Dec 18, 2008	Feb	CAHN
		@		EQ 300MG BASE	N021976	001	Jun 23, 2006	Feb	CAHN
				EQ 400MG BASE	N021976	003	Oct 21, 2008	Feb	CAHN
		+		EQ 600MG BASE	N021976	002	Feb 25, 2008	Feb	CAHN

DESLORATADINE

TABLET; ORAL
DESLORATADINE

	AB		MYLAN PHARMS INC	5MG	A078351	001	Feb 10, 2012	Jan	NEWA

DESMOPRESSIN ACETATE

SOLUTION; NASAL
DDAVP

>D>		+	SANOFI AVENTIS US	0.01%	N017922	001		Mar	CFTG
>A>	AB	+		0.01%	N017922	001		Mar	CFTG
>A>			DESMOPRESSIN ACETATE						
>A>	AB		SUN PHARM INDS	0.01%	A077212	001	Apr 12, 2012	Mar	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
VIORELE

>A>	AB		GLENMARK GENERICS	.15MG,N/A; 0.02MG,0.01MG	A091346	001	Apr 02, 2012	Mar	NEWA

DESONIDE

LOTION; TOPICAL
DESONIDE

	AB		FOUGERA PHARMS	0.05%	A075860	001	Mar 19, 2002	Jan	CAHN

OINTMENT; TOPICAL
DESONIDE

	AB		FOUGERA PHARMS	0.05%	A075751	001	Mar 12, 2001	Jan	CAHN

DESOXIMETASONE

CREAM; TOPICAL
DESOXIMETASONE

	AB		FOUGERA PHARMS	0.25%	A078369	001	Jun 29, 2010	Jan	CAHN

OINTMENT; TOPICAL
DESOXIMETASONE

>D>	AB		TARO	0.25%	A074286	001	Jun 07, 1996	Mar	CRLD
>A>	AB	+		0.25%	A074286	001	Jun 07, 1996	Mar	CRLD
>D>			TOPICORT						
>D>	AB	+	TARO PHARMS NORTH	0.25%	N018763	001	Sep 30, 1983	Mar	DISC
>A>			@	0.25%	N018763	001	Sep 30, 1983	Mar	DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

	AP	+	APP PHARMS LLC	EQ 10MG PHOSPHATE/ML	A040572	001	Apr 22, 2005	Feb	CRLD

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE

	BX	+	FOUGERA PHARMS	0.05%	A076263	001	Dec 20, 2002	Jan	CAHN
	AB1	+		0.05%	A075187	001	Mar 30, 1998	Jan	CAHN

OINTMENT; TOPICAL
DIFLORASONE DIACETATE

	AB		FOUGERA PHARMS	0.05%	A075374	001	Apr 27, 1999	Jan	CAHN

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL

	AB		EMCURE PHARMS USA	500MG	A202845	001	Mar 08, 2012	Feb	NEWA
	AB	+	TEVA	500MG	A073673	001	Jul 31, 1992	Feb	CTEC

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION
DILTIAZEM HYDROCHLORIDE

			@ TEVA PARENTERAL	5MG/ML	A074894	001	Aug 26, 1997	Jan	DISC

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

>D>			BENADRYL						
>D>	AP	+	MCNEIL CONS	50MG/ML	N006146	002		Mar	DISC
>A>			@	50MG/ML	N006146	002		Mar	DISC

			INJECTABLE; INJECTION							
>D>			BENADRYL PRESERVATIVE FREE							
>D>	AP	+	MCNEIL CONS	50MG/ML	N009486	001			Mar	DISC
>A>			@	50MG/ML	N009486	001			Mar	DISC
			DIPYRIDAMOLE							
			INJECTABLE; INJECTION							
			DIPYRIDAMOLE							
			@ TEVA PARENTERAL	5MG/ML	A074952	001	Nov 26, 1997		Jan	DISC
			TABLET; ORAL							
			DIPYRIDAMOLE							
	AB		PROSAM LABS	25MG	A040542	001	Apr 21, 2006		Feb	CAHN
	AB			50MG	A040542	002	Apr 21, 2006		Feb	CAHN
	AB			75MG	A040542	003	Apr 21, 2006		Feb	CAHN
			DIVALPROEX SODIUM							
			TABLET, EXTENDED RELEASE; ORAL							
			DIVALPROEX SODIUM							
	AB		DR REDDYS LABS LTD	EQ 250MG VALPROIC ACID	A090161	001	Mar 15, 2012		Feb	NEWA
	AB		REDDYS	EQ 500MG VALPROIC ACID	A090070	001	Mar 12, 2012		Feb	NEWA
			DOCETAXEL							
			INJECTABLE; INJECTION							
			DOCETAXEL							
	AP		ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011		Jan	CTEC
	AP			80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011		Jan	CTEC
	AP		APOTEX INC	20MG/0.5ML (40MG/ML)	N022312	001	Jan 11, 2012		Jan	NEWA
	AP			80MG/2ML (40MG/ML)	N022312	002	Jan 11, 2012		Jan	NEWA
			DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE							
			SOLUTION/DROPS; OPHTHALMIC							
			COSOPT PF							
		+	MERCK SHARP DOHME	EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012		Feb	NEWA
			DOXAZOSIN MESYLATE							
			TABLET; ORAL							
			DOXAZOSIN MESYLATE							
			@ NESHER PHARMS	EQ 1MG BASE	A075609	001	Oct 18, 2000		Feb	DISC
			@	EQ 2MG BASE	A075609	002	Oct 18, 2000		Feb	DISC
			@	EQ 4MG BASE	A075609	003	Oct 18, 2000		Feb	DISC
			@	EQ 8MG BASE	A075609	004	Oct 18, 2000		Feb	DISC
			DOXEPIN HYDROCHLORIDE							
			CREAM; TOPICAL							
			ZONALON							
		+	FOUGERA PHARMS	5%	N020126	001	Apr 01, 1994		Jan	CAHN
			DOXORUBICIN HYDROCHLORIDE							
			INJECTABLE; INJECTION							
			DOXORUBICIN HYDROCHLORIDE							
	AP		ONCO THERAPIES LTD	2MG/ML	A200901	001	Feb 14, 2012		Jan	NEWA
	AP		SUN PHARM INDS	2MG/ML	A091418	001	Feb 15, 2012		Jan	NEWA
			INJECTABLE, LIPOSOMAL; INJECTION							
			DOXIL							
		+	JANSSEN R AND D	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995		Jan	CAHN
		+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000		Jan	CAHN

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

>D>	AB	SANDOZ	EQ 50MG BASE	A065032	001	Jun 30, 2000	Mar	DISC
>D>	AB		EQ 100MG BASE	A065032	002	Jun 30, 2000	Mar	DISC
>A>		@ SANDOZ INC	EQ 50MG BASE	A065032	001	Jun 30, 2000	Mar	DISC
>A>		@	EQ 100MG BASE	A065032	002	Jun 30, 2000	Mar	DISC

TABLET; ORAL
DOXYCYCLINE

>D>	AB	SANDOZ	EQ 50MG BASE	A065353	001	Nov 27, 2006	Mar	DISC
>D>	AB		EQ 75MG BASE	A065353	002	Nov 27, 2006	Mar	DISC
>D>	AB		EQ 100MG BASE	A065353	003	Nov 27, 2006	Mar	DISC
>A>		@ SANDOZ INC	EQ 50MG BASE	A065353	001	Nov 27, 2006	Mar	DISC
>A>		@	EQ 75MG BASE	A065353	002	Nov 27, 2006	Mar	DISC
>A>		@	EQ 100MG BASE	A065353	003	Nov 27, 2006	Mar	DISC

DOXYCYCLINE HYCLATE

TABLET, DELAYED RELEASE; ORAL
DORYX

AB	+	MAYNE PHARMA	EQ 150MG BASE	N050795	003	Jun 20, 2008	Jan	CTEC

DOXYCYCLINE HYCLATE

AB		MYLAN PHARMS INC	EQ 150MG BASE	A091052	001	Feb 08, 2012	Jan	NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL
ANGELIQ

		BAYER HLTHCARE	0.25MG;0.5MG	N021355	001	Feb 29, 2012	Feb	NEWA

ECONAZOLE NITRATE

CREAM; TOPICAL
ECONAZOLE NITRATE

AB	+	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Jan	CAHN

ENALAPRIL MALEATE

TABLET; ORAL
ENALAPRIL MALEATE

		@ SANDOZ INC	2.5MG	A075621	001	Aug 22, 2000	Feb	DISC
		@	2.5MG	A075496	001	Aug 22, 2000	Jan	DISC
		@	5MG	A075621	002	Aug 22, 2000	Feb	DISC
		@	5MG	A075496	002	Aug 22, 2000	Jan	DISC
		@	10MG	A075621	003	Aug 22, 2000	Feb	DISC
		@	10MG	A075459	001	Aug 22, 2000	Jan	DISC
		@	20MG	A075621	004	Aug 22, 2000	Feb	DISC
		@	20MG	A075459	002	Aug 22, 2000	Jan	DISC

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

>D>	AB	SANDOZ	5MG;12.5MG	A076116	001	Sep 19, 2001	Mar	DISC
>D>	AB		10MG;25MG	A076116	002	Sep 19, 2001	Mar	DISC
>A>		@ SANDOZ INC	5MG;12.5MG	A076116	001	Sep 19, 2001	Mar	DISC
>A>		@	10MG;25MG	A076116	002	Sep 19, 2001	Mar	DISC

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
EPINASTINE HYDROCHLORIDE

>A>	AT		LUITPOLD	0.05%	A090951	001	Oct 31, 2011	Mar	CAHN
>D>	AT		PHARMAFORCE	0.05%	A090951	001	Oct 31, 2011	Mar	CAHN

EPINEPHRINE

INJECTABLE; ******
ADRENACLICK

>A>	BX	+	COREPHARMA	EQ 0.15MG /DELIVERY	N020800	003	Nov 25, 2009	Mar	CAHN
>A>	BX	+		EQ 0.3MG /DELIVERY	N020800	004	Nov 25, 2009	Mar	CAHN

TWINJECT 0.15

>A>	BX	+	COREPHARMA	EQ 0.15MG /DELIVERY	N020800	002	May 28, 2004	Mar	CAHN

TWINJECT 0.3

>A>	BX	+	COREPHARMA	EQ 0.3MG /DELIVERY	N020800	001	May 30, 2003	Mar	CAHN

INJECTABLE; IM-SC
ADRENACLICK

>D>	BX	+	SHIONOGI INC	EQ 0.15MG /DELIVERY	N020800	003	Nov 25, 2009	Mar	CAHN
>D>	BX	+		EQ 0.3MG /DELIVERY	N020800	004	Nov 25, 2009	Mar	CAHN

TWINJECT 0.15

>D>	BX	+	SHIONOGI INC	EQ 0.15MG /DELIVERY	N020800	002	May 28, 2004	Mar	CAHN

TWINJECT 0.3

>D>	BX	+	SHIONOGI INC	EQ 0.3MG /DELIVERY	N020800	001	May 30, 2003	Mar	CAHN

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
EPIRUBICIN HYDROCHLORIDE

>A>	AP		CIPLA LTD	50MG/25ML (2MG/ML)	A065361	001	Oct 22, 2007	Mar	CAHN
>A>	AP			200MG/100ML (2MG/ML)	A065361	002	Oct 22, 2007	Mar	CAHN
>A>	AP		HISUN PHARM HANGZHOU	50MG/25ML (2MG/ML)	A090075	001	Mar 25, 2010	Mar	CAHN
>A>	AP			200MG/100ML (2MG/ML)	A090075	002	Mar 25, 2010	Mar	CAHN
>A>	AP		ONCO THERAPIES LTD	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	Mar	NEWA
>A>	AP			200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	Mar	NEWA
>D>	AP		WATSON LABS	200MG/100ML (2MG/ML)	A065361	002	Oct 22, 2007	Mar	CAHN
>D>	AP			50MG/25ML (2MG/ML)	A065361	001	Oct 22, 2007	Mar	CAHN
>D>	AP		X GEN PHARMS	50MG/25ML (2MG/ML)	A090075	001	Mar 25, 2010	Mar	CAHN
>D>	AP			200MG/100ML (2MG/ML)	A090075	002	Mar 25, 2010	Mar	CAHN

ERYTHROMYCIN

GEL; TOPICAL
ERYTHROMYCIN

	AT		FOUGERA PHARMS	2%	A064184	001	Sep 30, 1997	Jan	CAHN

SOLUTION; TOPICAL
C-SOLVE-2

	AT		FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Jan	CMFD

SWAB; TOPICAL
ERYTHROMYCIN

	AT	+	FOUGERA PHARMS	2%	A065320	001	Jul 25, 2006	Jan	CAHN

ESCITALOPRAM OXALATE

SOLUTION; ORAL
ESCITALOPRAM OXALATE

	AA		AMNEAL PHARMS	EQ 5MG BASE/5ML	A202227	001	Mar 14, 2012	Feb	NEWA
>A>	AA		AUROBINDO PHARMA LTD	EQ 5MG BASE/5ML	A079062	001	Apr 02, 2012	Mar	NEWA

		SOLUTION; ORAL							
		LEXAPRO							
AA	+	FOREST LABS	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Feb	CFTG	
		TABLET; ORAL							
		ESCITALOPRAM OXALATE							
AB		IVAX SUB TEVA PHARMS	EQ 5MG BASE	A076765	001	Mar 14, 2012	Feb	NEWA	
AB			EQ 10MG BASE	A076765	002	Mar 14, 2012	Feb	NEWA	
AB			EQ 20MG BASE	A076765	003	Mar 14, 2012	Feb	NEWA	
		LEXAPRO							
AB		FOREST LABS	EQ 5MG BASE	N021323	001	Aug 14, 2002	Feb	CFTG	
AB			EQ 10MG BASE	N021323	002	Aug 14, 2002	Feb	CFTG	
AB	+		EQ 20MG BASE	N021323	003	Aug 14, 2002	Feb	CFTG	
		ESTRADIOL; NORETHINDRONE ACETATE							
		TABLET; ORAL							
		ESTRADIOL AND NORETHINDRONE ACETATE							
AB		TEVA PHARMS USA	0.5MG;0.1MG	A200747	001	Mar 08, 2012	Feb	NEWA	
		ETHINYL ESTRADIOL; LEVONORGESTREL							
		TABLET; ORAL-28							
>A>		FALMINA							
>A> AB1		NOVAST LABS LTD	0.02MG;0.1MG	A090721	001	Mar 28, 2012	Mar	NEWA	
		MARLISSA							
AB		GLENMARK GENERICS	0.03MG;0.15MG	A091452	001	Feb 29, 2012	Feb	NEWA	
		ETHINYL ESTRADIOL; NORETHINDRONE							
		TABLET; ORAL-28							
		ALYACEN 1/35							
AB		GLENMARK GENERICS	0.035MG;1MG	A091634	001	Jan 19, 2012	Jan	NEWA	
		ALYACEN 7/7/7							
AB		GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A091636	001	Jan 19, 2012	Jan	NEWA	
>A>		WERA							
>A> AB		NOVAST LABS LTD	0.035MG;0.5MG	A091204	001	Mar 27, 2012	Mar	NEWA	
		ETHINYL ESTRADIOL; NORGESTIMATE							
		TABLET; ORAL-28							
		NORGESTIMATE AND ETHINYL ESTRADIOL							
>A> AB		GLENMARK GENERICS	0.035MG;0.25MG	A200538	001	Apr 05, 2012	Mar	NEWA	
		ETHINYL ESTRADIOL; NORGESTREL							
		TABLET; ORAL-28							
>A>		ELINEST							
>A> AB		NOVAST LABS LTD	0.03MG;0.3MG	A091105	001	Mar 28, 2012	Mar	NEWA	
		ETODOLAC							
		TABLET; ORAL							
		ETODOLAC							
AB		PROSAM LABS	400MG	A074819	001	Feb 28, 1997	Feb	CMFD	
AB			500MG	A074819	002	Apr 28, 1998	Feb	CMFD	
		ETOPOSIDE							
		CAPSULE; ORAL							
		VEPESID							
	@	CORDEN PHARMA	50MG	N019557	001	Dec 30, 1986	Feb	CAHN	
	@		100MG	N019557	002	Dec 30, 1986	Feb	CAHN	

			INJECTABLE; INJECTION							
			ETOPOSIDE							
>D>	AP		APP PHARMS	20MG/ML	A074983	001	Sep 30, 1998	Mar	CRLD	
>A>	AP	+	APP PHARMS LLC	20MG/ML	A074983	001	Sep 30, 1998	Mar	CRLD	
>D>	AP	+	BEDFORD	20MG/ML	A074290	001	Jul 17, 1995	Mar	CRLD	
>A>	AP			20MG/ML	A074290	001	Jul 17, 1995	Mar	CRLD	
			VEPESID							
			@ CORDEN PHARMA	20MG/ML	N018768	001	Nov 10, 1983	Feb	CAHN	
			ETRAVIRINE							
			TABLET; ORAL							
			INTELENCE							
>A>			JANSSEN R AND D	25MG	N022187	003	Mar 26, 2012	Mar	NEWA	
				100MG	N022187	001	Jan 18, 2008	Feb	CAHN	
		+		200MG	N022187	002	Dec 22, 2010	Feb	CAHN	
			EXENATIDE SYNTHETIC							
			FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS							
			BYDUREON							
		+	AMYLIN	2MG/VIAL	N022200	001	Jan 27, 2012	Jan	NEWA	
			EZETIMIBE							
			TABLET; ORAL							
			ZETIA							
		+	MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002	Feb	CAHN	
		+	MSP SINGAPORE	10MG	N021445	001	Oct 25, 2002	Jan	CAHN	
			EZETIMIBE; SIMVASTATIN							
			TABLET; ORAL							
			VYTORIN							
			MSD INTL	10MG;10MG	N021687	001	Jul 23, 2004	Jan	CAHN	
				10MG;20MG	N021687	002	Jul 23, 2004	Jan	CAHN	
				10MG;40MG	N021687	003	Jul 23, 2004	Jan	CAHN	
		+		10MG;80MG	N021687	004	Jul 23, 2004	Jan	CAHN	
			FAMCICLOVIR							
			TABLET; ORAL							
			FAMCICLOVIR							
	AB		MACLEODS PHARMS LTD	125MG	A201022	001	Jan 12, 2012	Jan	NEWA	
	AB			250MG	A201022	002	Jan 12, 2012	Jan	NEWA	
	AB			500MG	A201022	003	Jan 12, 2012	Jan	NEWA	
			FAMOTIDINE							
			TABLET; ORAL							
			PEPCID							
	AB		MARATHON PHARMS	20MG	N019462	001	Oct 15, 1986	Jan	CAHN	
	AB	+		40MG	N019462	002	Oct 15, 1986	Jan	CAHN	
			TABLET, ORALLY DISINTEGRATING; ORAL							
			FLUXID							
			@ UCB INC	20MG	N021712	001	Sep 24, 2004	Jan	CAHN	
			@	40MG	N021712	002	Sep 24, 2004	Jan	CAHN	
			FENOFIBRATE							
			CAPSULE; ORAL							
			ANTARA (MICRONIZED)							
	AB		LUPIN ATLANTIS	43MG	N021695	001	Nov 30, 2004	Feb	CFTG	

CAPSULE; ORAL
ANTARA (MICRONIZED)

	AB	+	LUPIN ATLANTIS	130MG	N021695	003	Nov 30, 2004	Feb	CFTG

FENOFIBRATE (MICRONIZED)

	AB		DR REDDYS LABS SA	43MG	A090859	001	Mar 01, 2012	Feb	NEWA
	AB			130MG	A090859	002	Mar 01, 2012	Feb	NEWA

TABLET; ORAL
FENOFIBRATE

>D>	AB		IMPAX LABS	160MG	A076509	002	Mar 26, 2008	Mar	CRLD
>A>	AB	+		160MG	A076509	002	Mar 26, 2008	Mar	CRLD
>D>	AB		TEVA	54MG	A076433	001	May 13, 2005	Mar	DISC
>A>		@		54MG	A076433	001	May 13, 2005	Mar	DISC
>D>	AB	+		160MG	A076433	002	May 13, 2005	Mar	DISC
>A>		@		160MG	A076433	002	May 13, 2005	Mar	DISC
>A>	AB		VALEANT INTL	48MG	A090715	001	Apr 05, 2012	Mar	NEWA
>A>	AB			145MG	A090715	002	Apr 05, 2012	Mar	NEWA

FENTANYL

SPRAY; SUBLINGUAL
SUBSYS

>D>			INSYS THERAP	0.1MCG	N202788	001	Jan 04, 2012	Mar	CPOT
>A>				0.1MG	N202788	001	Jan 04, 2012	Mar	CPOT
				0.1MCG	N202788	001	Jan 04, 2012	Jan	NEWA
>D>				0.2MCG	N202788	002	Jan 04, 2012	Mar	CPOT
>A>				0.2MG	N202788	002	Jan 04, 2012	Mar	CPOT
				0.2MCG	N202788	002	Jan 04, 2012	Jan	NEWA
>D>		+		0.4MCG	N202788	003	Jan 04, 2012	Mar	CPOT
>A>		+		0.4MG	N202788	003	Jan 04, 2012	Mar	CPOT
		+		0.4MCG	N202788	003	Jan 04, 2012	Jan	NEWA
>D>				0.6MCG	N202788	004	Jan 04, 2012	Mar	CPOT
>A>				0.6MG	N202788	004	Jan 04, 2012	Mar	CPOT
				0.6MCG	N202788	004	Jan 04, 2012	Jan	NEWA
>D>				0.8MCG	N202788	005	Jan 04, 2012	Mar	CPOT
>A>				0.8MG	N202788	005	Jan 04, 2012	Mar	CPOT
				0.8MCG	N202788	005	Jan 04, 2012	Jan	NEWA

FENTANYL CITRATE

SPRAY, METERED; NASAL
LAZANDA

			ARCHIMEDES	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Jan	CPOT
		+		EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Jan	CPOT

TROCHE/LOZENGE; TRANSMUCOSAL
FENTANYL CITRATE

	AB		PAR PHARM	EQ 0.2MG BASE	A077312	001	Oct 30, 2009	Feb	CAHN
	AB			EQ 0.4MG BASE	A077312	002	Oct 30, 2009	Feb	CAHN
	AB			EQ 0.6MG BASE	A077312	003	Oct 30, 2009	Feb	CAHN
	AB			EQ 0.8MG BASE	A077312	004	Oct 30, 2009	Feb	CAHN
	AB			EQ 1.2MG BASE	A077312	005	Oct 30, 2009	Feb	CAHN
	AB			EQ 1.6MG BASE	A077312	006	Oct 30, 2009	Feb	CAHN

FLUCONAZOLE

INJECTABLE; INJECTION
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

	AP		HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764	001	Jan 30, 2012	Jan	NEWA
	AP			400MG/200ML (2MG/ML)	A078764	002	Jan 30, 2012	Jan	NEWA

			INJECTABLE; INJECTION							
			FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	AP		HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078698	001	Jan 30, 2012	Jan	NEWA	
	AP			400MG/200ML (2MG/ML)	A078698	002	Jan 30, 2012	Jan	NEWA	
			TABLET; ORAL							
			FLUCONAZOLE							
		@	PLIVA	50MG	A076424	001	Jul 29, 2004	Feb	DISC	
		@		100MG	A076424	002	Jul 29, 2004	Feb	DISC	
		@		150MG	A076424	003	Jul 29, 2004	Feb	DISC	
		@		200MG	A076424	004	Jul 29, 2004	Feb	DISC	
			FLUDARABINE PHOSPHATE							
			INJECTABLE; INJECTION							
>D>			FLUDARA							
>D>	AP	+	GENZYME	50MG/VIAL	N020038	001	Apr 18, 1991	Mar	DISC	
>A>		@	GENZYME CORP	50MG/VIAL	N020038	001	Apr 18, 1991	Mar	DISC	
			FLUDARABINE PHOSPHATE							
>D>	AP		HOSPIRA	50MG/VIAL	A077790	001	Apr 06, 2007	Mar	CRLD	
>A>	AP	+		50MG/VIAL	A077790	001	Apr 06, 2007	Mar	CRLD	
			FLUMAZENIL							
			INJECTABLE; INJECTION							
			FLUMAZENIL							
		@	TEVA PARENTERAL	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004	Jan	DISC	
		@		1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004	Jan	DISC	
			FLUOCINOLONE ACETONIDE							
			OIL/DROPS; OTIC							
			FLUOCINOLONE ACETONIDE							
	AT		IDENTI PHARMS INC	0.01%	A091306	001	Oct 17, 2011	Jan	CPOT	
			FLUOCINONIDE							
			CREAM; TOPICAL							
			FLUOCINONIDE EMULSIFIED BASE							
	AB2		FOUGERA PHARMS	0.05%	A076586	001	Jun 23, 2004	Jan	CAHN	
			OINTMENT; TOPICAL							
			FLUOCINONIDE							
	AB		FOUGERA PHARMS	0.05%	A074905	001	Aug 26, 1997	Jan	CAHN	
			FLUOROURACIL							
			CREAM; TOPICAL							
			FLUOROPLEX							
		+	AQUA PHARMS	1%	N016988	001		Jan	CAHN	
			FLUTAMIDE							
			CAPSULE; ORAL							
			FLUTAMIDE							
>D>	AB		IVAX SUB TEVA PHARMS	125MG	A075780	001	Sep 19, 2001	Mar	CRLD	
>A>	AB	+		125MG	A075780	001	Sep 19, 2001	Mar	CRLD	
>D>	AB	+	SANDOZ	125MG	A075818	001	Sep 18, 2001	Mar	CRLD	
>A>	AB		SANDOZ INC	125MG	A075818	001	Sep 18, 2001	Mar	CRLD	
			FLUTICASONE PROPIONATE							
			CREAM; TOPICAL							
			CUTIVATE							
	AB	+	FOUGERA PHARMS	0.05%	N019958	001	Dec 18, 1990	Jan	CAHN	

CREAM; TOPICAL
FLUTICASONE PROPIONATE

AB	FOUGERA PHARMS	0.05%	A076451	001	May 14, 2004	Jan	CAHN

OINTMENT; TOPICAL
FLUTICASONE PROPIONATE

AB	FOUGERA PHARMS	0.005%	A076300	001	May 14, 2004	Jan	CAHN

FLUVASTATIN SODIUM

CAPSULE; ORAL
FLUVASTATIN SODIUM

>A>									
>A>	AB	MYLAN PHARMS INC	EQ 20MG BASE	A090595	001	Apr 11, 2012	Mar	NEWA
>A>	AB		EQ 40MG BASE	A090595	002	Apr 11, 2012	Mar	NEWA
		LESCOL						
>D>		NOVARTIS	EQ 20MG BASE	N020261	001	Dec 31, 1993	Mar	CFTG
>A>	AB		EQ 20MG BASE	N020261	001	Dec 31, 1993	Mar	CFTG
>D>	+		EQ 40MG BASE	N020261	002	Dec 31, 1993	Mar	CFTG
>A>	AB +		EQ 40MG BASE	N020261	002	Dec 31, 1993	Mar	CFTG

FOSINOPRIL SODIUM

TABLET; ORAL
MONOPRIL

>D>								
>D>	AB	BRISTOL MYERS SQUIBB	10MG	N019915	002	May 16, 1991	Mar	DISC
>A>		@	10MG	N019915	002	May 16, 1991	Mar	DISC
>D>	AB		20MG	N019915	003	May 16, 1991	Mar	DISC
>A>		@	20MG	N019915	003	May 16, 1991	Mar	DISC
>D>	AB +		40MG	N019915	004	Mar 28, 1995	Mar	DISC
>A>		@	40MG	N019915	004	Mar 28, 1995	Mar	DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION
FOSPHENYTOIN SODIUM

>D>	AP	TEVA PARENTERAL	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007	Mar	DISC
>A>		@	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007	Mar	DISC

GABAPENTIN

SOLUTION; ORAL
GABAPENTIN

>A>	AA	AMNEAL PHARMS	250MG/5ML	A202024	001	Mar 23, 2012	Mar	NEWA

GLYCOPYRROLATE

TABLET; ORAL
GLYCOPYRROLATE

	AA	NEXGEN PHARMA	1.5MG	A091522	001	Mar 12, 2012	Feb	NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION
GRANISETRON HYDROCHLORIDE

>A>	AP	CIPLA LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262	001	Dec 31, 2007	Mar	CAHN
>A>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	Mar	CAHN
>A>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	Mar	CAHN
>D>	AP	WATSON LABS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262	001	Dec 31, 2007	Mar	CAHN
>D>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	Mar	CAHN
>D>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	Mar	CAHN

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL
GRIFULVIN V

AB	+	VALEANT PHARM NORTH	125MG/5ML	A062483	001	Jan 26, 1984	Feb	CAHN

HALOBETASOL PROPIONATE

CREAM; TOPICAL
HALOBETASOL PROPIONATE

AB		FOUGERA PHARMS	0.05%	A077001	001	Dec 16, 2004	Jan	CAHN

OINTMENT; TOPICAL
HALOBETASOL PROPIONATE

AB		FOUGERA PHARMS	0.05%	A076903	001	Dec 16, 2004	Jan	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

>D>		HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER							
>D>		@ BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985	Mar	DISC
>A>		@	2,000 UNITS/100ML	N018814	002	Jul 09, 1985	Mar	DISC
>D>		HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER							
>D>	AP	BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983	Mar	DISC
>A>		@	4,000 UNITS/100ML	N018814	001	Oct 31, 1983	Mar	DISC
>D>		HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER							
>D>	AP	BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985	Mar	DISC
>A>		@	5,000 UNITS/100ML	N018814	003	Jul 09, 1985	Mar	DISC
>D>	AP		10,000 UNITS/100ML	N018814	004	Jul 02, 1987	Mar	DISC
>A>		@	10,000 UNITS/100ML	N018814	004	Jul 02, 1987	Mar	DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDROCHLOROTHIAZIDE

AB		LANNETT HOLDINGS INC	12.5MG	A091662	001	Jan 27, 2012	Jan	NEWA

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
AVALIDE

>D>		+ SANOFI AVENTIS	12.5MG;150MG	N020758	002	Sep 30, 1997	Mar	CFTG
>A>	AB	+	12.5MG;150MG	N020758	002	Sep 30, 1997	Mar	CFTG
>D>		+	12.5MG;300MG	N020758	003	Aug 31, 1998	Mar	CFTG
>A>	AB	+	12.5MG;300MG	N020758	003	Aug 31, 1998	Mar	CFTG
		+	12.5MG;300MG	N020758	003	Aug 31, 1998	Feb	CRLD
>A>		IRBESARTAN AND HYDROCHLOROTHIAZIDE							
>A>	AB	TEVA	12.5MG;150MG	A077369	001	Mar 30, 2012	Mar	NEWA
>A>	AB		12.5MG;300MG	A077369	002	Mar 30, 2012	Mar	NEWA
>A>			25MG;300MG	A077369	003	Mar 30, 2012	Mar	NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC LTD	12.5MG;50MG	A091617	001	Feb 17, 2012	Feb	NEWA
AB			12.5MG;100MG	A091617	002	Feb 17, 2012	Feb	NEWA
AB			25MG;100MG	A091617	003	Feb 17, 2012	Feb	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

		ASTRAZENECA	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jan	CMFD
			12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jan	CMFD
			12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jan	CMFD

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB		MYLAN	50MG;100MG	A076792	003	Aug 20, 2004	Jan	CTEC
AB		SUN PHARM INDS	25MG;50MG	A090654	001	Jan 19, 2012	Jan	NEWA
AB			25MG;100MG	A090654	002	Jan 19, 2012	Jan	NEWA
AB			50MG;100MG	A090654	003	Jan 19, 2012	Jan	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

		@ PADDOCK LLC	12.5MG;7.5MG	A090096	001	Sep 25, 2008	Jan	DISC
		@	12.5MG;15MG	A090096	002	Sep 25, 2008	Jan	DISC
		@	25MG;15MG	A090096	003	Sep 25, 2008	Jan	DISC

HYDROCORTISONE

LOTION; TOPICAL

HYDROCORTISONE

AT	+	FOUGERA PHARMS	2.5%	A040351	001	Jul 25, 2000	Jan	CAHN

OINTMENT; TOPICAL

HYDROCORTISONE

AT	+	FOUGERA PHARMS	1%	A080692	001		Jan	CAHN

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

CARMOL HC

AT		FOUGERA PHARMS	1%;10%	A080505	001		Jan	CAHN

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

>D>	AB		TARO	0.2%	A075042	001	Aug 25, 1998	Mar	CRLD
>A>	AB	+		0.2%	A075042	001	Aug 25, 1998	Mar	CRLD
>D>			WESTCORT						
>D>	AB	+	RANBAXY	0.2%	N017950	001		Mar	DISC
>A>			@	0.2%	N017950	001		Mar	DISC

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB		FOUGERA PHARMS	0.2%	A075085	001	Jul 31, 2001	Jan	CAHN

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

AB	+	SHIRE LLC	50MG	N011949	001		Jan	CAHN

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL
HYDROXYZINE HYDROCHLORIDE

		@	STI PHARMA LLC	10MG/5ML	A086880	001			Feb	CAHN

IBANDRONATE SODIUM

TABLET; ORAL
BONIVA

>A>	AB	+	HOFFMANN LA ROCHE	EQ 150MG BASE	N021455	002	Mar 24, 2005		Mar	CFTG
>D>		+	ROCHE	EQ 150MG BASE	N021455	002	Mar 24, 2005		Mar	CFTG

IBANDRONATE SODIUM

>A>	AB		APOTEX INC	EQ 150MG BASE	A078948	001	Mar 19, 2012		Mar	NEWA
>A>	AB		MYLAN PHARMS INC	EQ 150MG BASE	A078995	001	Mar 19, 2012		Mar	NEWA
>A>	AB		ORCHID HLTHCARE	EQ 150MG BASE	A078998	001	Mar 19, 2012		Mar	NEWA
>A>	AB		WATSON LABS INC	EQ 150MG BASE	A079003	001	Mar 20, 2012		Mar	NEWA

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS
NEOPROFEN

>D>		+	LUNDBECK INC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006		Mar	CAHN
>A>		+	LUNDBECK LLC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006		Mar	CAHN

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDARUBICIN HYDROCHLORIDE

>D>		+	TEVA PARENTERAL	5MG/VIAL	A065037	003	May 01, 2002		Mar	DISC
>A>			@	5MG/VIAL	A065037	003	May 01, 2002		Mar	DISC
>D>		+		10MG/VIAL	A065037	002	May 01, 2002		Mar	DISC
>A>			@	10MG/VIAL	A065037	002	May 01, 2002		Mar	DISC
>D>		+		20MG/VIAL	A065037	001	May 01, 2002		Mar	DISC
>A>			@	20MG/VIAL	A065037	001	May 01, 2002		Mar	DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL
IMIPRAMINE HYDROCHLORIDE

	AB		PROSAM LABS	10MG	A040753	001	Feb 28, 2008		Feb	CMFD
	AB			25MG	A040752	001	Feb 28, 2008		Feb	CMFD
	AB			50MG	A040751	001	Feb 28, 2008		Feb	CMFD

IMIQUIMOD

CREAM; TOPICAL
IMIQUIMOD

>A>	AB		APOTEX INC	5%	A091308	001	Apr 06, 2012		Mar	NEWA
	AB		FOUGERA PHARMS	5%	A078548	001	Feb 25, 2010		Jan	CAHN
	AB		GLENMARK GENERICS	5%	A201994	001	Mar 06, 2012		Feb	NEWA

INDOMETHACIN SODIUM

INJECTABLE; INJECTION
INDOCIN

>D>	AP	+	LUNDBECK INC	EQ 1MG BASE/VIAL	N018878	001	Jan 30, 1985		Mar	CAHN
>A>	AP	+	LUNDBECK LLC	EQ 1MG BASE/VIAL	N018878	001	Jan 30, 1985		Mar	CAHN

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

		LEO PHARMA AS	0.015%	N202833	001	Jan 23, 2012	Jan		NEWA
	+		0.05%	N202833	002	Jan 23, 2012	Jan		NEWA

IRBESARTAN

TABLET; ORAL

AVAPRO

>D>		SANOFI AVENTIS US	75MG	N020757	001	Sep 30, 1997	Mar		CFTG
>A>	AB		75MG	N020757	001	Sep 30, 1997	Mar		CFTG
>D>			150MG	N020757	002	Sep 30, 1997	Mar		CFTG
>A>	AB		150MG	N020757	002	Sep 30, 1997	Mar		CFTG
>D>	+		300MG	N020757	003	Sep 30, 1997	Mar		CFTG
>A>	AB	+	300MG	N020757	003	Sep 30, 1997	Mar		CFTG

IRBESARTAN

>A>									
>A>	AB	TEVA PHARMS	75MG	A077159	001	Mar 30, 2012	Mar		NEWA
>A>	AB		150MG	A077159	002	Mar 30, 2012	Mar		NEWA
>A>	AB		300MG	A077159	003	Mar 30, 2012	Mar		NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

>A>	AP	CIPLA LTD	40MG/2ML (20MG/ML)	A077219	001	Feb 20, 2008	Mar		CAHN
>A>	AP		100MG/5ML (20MG/ML)	A077219	002	Feb 20, 2008	Mar		CAHN
	AP	EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771	001	Feb 14, 2012	Jan		NEWA
	AP		100MG/5ML (20MG/ML)	A200771	002	Feb 14, 2012	Jan		NEWA
>A>	AP	HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016	001	Jan 28, 2009	Mar		CAHN
>A>	AP		100MG/5ML (20MG/ML)	A090016	002	Jan 28, 2009	Mar		CAHN
>D>	AP	TEVA PARENTERAL	500MG/25ML (20MG/ML)	A090101	001	Nov 26, 2008	Mar		DISC
>A>		@	500MG/25ML (20MG/ML)	A090101	001	Nov 26, 2008	Mar		DISC
>D>	AP	WATSON LABS	40MG/2ML (20MG/ML)	A077219	001	Feb 20, 2008	Mar		CAHN
>D>	AP		100MG/5ML (20MG/ML)	A077219	002	Feb 20, 2008	Mar		CAHN
>D>	AP	X-GEN PHARMS	40MG/2ML (20MG/ML)	A090016	001	Jan 28, 2009	Mar		CAHN
>D>	AP		100MG/5ML (20MG/ML)	A090016	002	Jan 28, 2009	Mar		CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

		@ SKYEPHARMA AG	60MG	A075166	001	Oct 07, 1999	Jan		DISC

ISOTRETINOIN

CAPSULE; ORAL

MYORISAN

	AB	DOUGLAS PHARMS	10MG	A076485	001	Jan 19, 2012	Jan		NEWA
	AB		20MG	A076485	002	Jan 19, 2012	Jan		NEWA
	AB		40MG	A076485	003	Jan 19, 2012	Jan		NEWA

IVACAFTOR

TABLET; ORAL

KALYDECO

	+	VERTEX PHARMS	150MG	N203188	001	Jan 31, 2012	Jan		NEWA

IVERMECTIN

LOTION; TOPICAL

SKLICE

+	SANOFI PASTEUR	0.5%	N202736	001	Feb 07, 2012	Feb	NEWA

KETOCONAZOLE

CREAM; TOPICAL

KETOCONAZOLE

AB	FOUGERA PHARMS	2%	A076294	001	Apr 28, 2004	Jan	CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

>A>	AP	GLAND PHARMA LTD	5MG/ML	A090699	001	Apr 03, 2012	Mar	NEWA

LACTULOSE

SOLUTION; ORAL

LACTULOSE

	AA	FRESENIUS KABI	10GM/15ML	A090503	001	Jan 25, 2012	Jan	NEWA

SOLUTION; ORAL, RECTAL

LACTULOSE

	AA	FRESENIUS KABI	10GM/15ML	A090502	001	Jan 25, 2012	Jan	NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

PREVACID

>D>	AB	TAKEDA PHARMS NA	15MG	N020406	001	May 10, 1995	Mar	CAHN
>D>	AB	+	30MG	N020406	002	May 10, 1995	Mar	CAHN
>A>	AB	TAKEDA PHARMS USA	15MG	N020406	001	May 10, 1995	Mar	CAHN
>A>	AB	+	30MG	N020406	002	May 10, 1995	Mar	CAHN

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

>D>

LANSOPRAZOLE

>D>	AB	TEVA PHARMS	15MG	A078730	001	Oct 15, 2010	Mar	DISC
>A>		@	15MG	A078730	001	Oct 15, 2010	Mar	DISC
>D>	AB		30MG	A078730	002	Oct 15, 2010	Mar	DISC
>A>		@	30MG	A078730	002	Oct 15, 2010	Mar	DISC

PREVACID

>D>	AB	TAKEDA PHARMS NA	15MG	N021428	001	Aug 30, 2002	Mar	CTEC
>D>	AB	+	30MG	N021428	002	Aug 30, 2002	Mar	CTEC
>A>		TAKEDA PHARMS USA	15MG	N021428	001	Aug 30, 2002	Mar	CTEC
>A>		+	30MG	N021428	002	Aug 30, 2002	Mar	CTEC

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

		@ SHIRE LLC	EQ 250MG BASE	N021468	001	Oct 26, 2004	Feb	CAHN
			EQ 500MG BASE	N021468	002	Oct 26, 2004	Feb	CAHN
			EQ 750MG BASE	N021468	003	Nov 23, 2005	Feb	CAHN
		+	EQ 1GM BASE	N021468	004	Nov 23, 2005	Feb	CAHN

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

>D>	AP	TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278	001	Sep 28, 1993	Mar	DISC
>A>		@	EQ 50MG BASE/VIAL	A081278	001	Sep 28, 1993	Mar	DISC

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

>A>	AP	HOSPIRA INC	500MG/ML (100MG/ML)	A202869	001	Apr 06, 2012	Mar	NEWA
	AP	PHARMAFORCE	500MG/5ML (100MG/ML)	A202143	001	Jan 31, 2012	Jan	NEWA

SOLUTION; ORAL

LEVETIRACETAM

	AA	HI-TECH PHARMACAL	100MG/ML	A090601	001	Feb 28, 2012	Feb	NEWA
>A>	AA	VINTAGE PHARMS	100MG/ML	A090079	001	Apr 11, 2012	Mar	NEWA

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

>A>	AB	CIPLA LTD	250MG	A076890	001	Mar 30, 2012	Mar	NEWA
>A>	AB		500MG	A076890	002	Mar 30, 2012	Mar	NEWA
>A>	AB		750MG	A076890	003	Mar 30, 2012	Mar	NEWA
>A>	AB	MACLEODS PHARMS LTD	250MG	A200839	001	Mar 22, 2012	Mar	NEWA
>A>	AB		500MG	A200839	002	Mar 22, 2012	Mar	NEWA
>A>	AB		750MG	A200839	003	Mar 22, 2012	Mar	NEWA
	AB	ORCHID HLTHCARE	250MG	A202200	001	Jan 30, 2012	Jan	NEWA
	AB		500MG	A202200	002	Jan 30, 2012	Jan	NEWA
	AB		750MG	A202200	003	Jan 30, 2012	Jan	NEWA

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

	AB	FOUGERA PHARMS	2.5%;2.5%	A076453	001	Aug 18, 2003	Jan	CAHN

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

		BOEHRINGER INGELHEIM	2.5MG;500MG	N201281	001	Jan 30, 2012	Jan	NEWA
			2.5MG;850MG	N201281	002	Jan 30, 2012	Jan	NEWA
	+		2.5MG;1GM	N201281	003	Jan 30, 2012	Jan	NEWA

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

	AA	HI-TECH PHARMA CO	2MG/ML	A200169	001	Jan 30, 2012	Jan	NEWA

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

		HOSPIRA	20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995	Jan	NEWA
			40GM/1000ML(40MG/ML)	N020309	005	Jan 18, 1995	Jan	NEWA

MALATHION

LOTION; TOPICAL

MALATHION

	AT	MYLAN PHARMS INC	0.5%	A078743	001	Mar 06, 2009	Feb	CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

>A>	AA	EPIC PHARMA LLC	12.5MG	A200294	001	Apr 13, 2012	Mar	NEWA

TABLET; ORAL
MECLIZINE HYDROCHLORIDE

>A>	AA		EPIC PHARMA LLC	25MG	A200294	002	Apr 13, 2012	Mar	NEWA

MEMANTINE HYDROCHLORIDE

TABLET; ORAL
MEMANTINE HYDROCHLORIDE

>D>									
>D>	AB		ORCHID HLTHCARE	5MG	A090044	001	Mar 12, 2012	Mar	DISC
>A>			@	5MG	A090044	001	Mar 12, 2012	Mar	DISC
	AB			5MG	A090044	001	Mar 12, 2012	Feb	NEWA
>D>	AB			10MG	A090044	002	Mar 12, 2012	Mar	DISC
>A>			@	10MG	A090044	002	Mar 12, 2012	Mar	DISC
	AB			10MG	A090044	002	Mar 12, 2012	Feb	NEWA

NAMENDA

>D>	AB		FOREST LABS	5MG	N021487	001	Oct 16, 2003	Mar	CTEC
>A>				5MG	N021487	001	Oct 16, 2003	Mar	CTEC
	AB			5MG	N021487	001	Oct 16, 2003	Feb	CTEC
>D>	AB	+		10MG	N021487	002	Oct 16, 2003	Mar	CTEC
>A>		+		10MG	N021487	002	Oct 16, 2003	Mar	CTEC
	AB	+		10MG	N021487	002	Oct 16, 2003	Feb	CTEC

MESALAMINE

SUPPOSITORY; RECTAL
ROWASA

			@ MEDA PHARMS	500MG	N019919	001	Dec 18, 1990	Jan	CAHN

MESNA

INJECTABLE; INTRAVENOUS
MESNA

	AP		MYLAN INSTITUTIONAL	100MG/ML	A076488	001	Mar 08, 2012	Feb	NEWA

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HYDROCHLORIDE

	AB		MARKSANS PHARMA	500MG	A090888	001	Mar 12, 2012	Feb	NEWA
	AB			850MG	A090888	002	Mar 12, 2012	Feb	NEWA
	AB			1GM	A090888	003	Mar 12, 2012	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

	AB1		INVENTIA HLTHCARE	500MG	A201991	001	Jan 18, 2012	Jan	NEWA

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET, EXTENDED RELEASE; ORAL
JANUMET XR

			MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	Feb	NEWA
				1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	Feb	NEWA
		+		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	Feb	NEWA

METHIMAZOLE

TABLET; ORAL
METHIMAZOLE

	AB		BOCA PHARMA	5MG	A202068	001	Mar 07, 2012	Feb	NEWA
	AB			10MG	A202068	002	Mar 07, 2012	Feb	NEWA

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

>D>		@ SOLCO HLTHCARE	500MG	A086989	001			Mar	CMFD
>A>	AA		500MG	A086989	001			Mar	CMFD
>D>		@	750MG	A086988	001			Mar	CMFD
>A>	AA		750MG	A086988	001			Mar	CMFD

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

	AP	APP PHARMS LLC	EQ 1GM BASE/VIAL	A040266	001	Feb 26, 1999		Jan	CMFD
	AP	PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A200171	001	Feb 27, 2012		Feb	NEWA

METHOTREXATE SODIUM

	AP	+ BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986		Feb	CTEC

METHOTREXATE SODIUM PRESERVATIVE FREE

	AP	+ MYLAN INSTITUTIONAL	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767	001	Apr 30, 2007		Feb	CAHN
>A>	AP	ONCO THERAPIES LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012		Mar	NEWA
>A>	AP		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012		Mar	NEWA
>A>	AP		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012		Mar	NEWA
>A>	AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012		Mar	NEWA
>A>	AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012		Mar	NEWA

METHYCLOTHIAZIDE

TABLET; ORAL

ENDURON

>D>		ABBOTT	2.5MG	N012524	001			Mar	DISC
>D>	AB	+	5MG	N012524	004			Mar	DISC
>A>		@ ABBOTT LABS PHARM	2.5MG	N012524	001			Mar	DISC
>A>		@	5MG	N012524	004			Mar	DISC

METHYCLOTHIAZIDE

>D>	AB	MYLAN	5MG	A087672	001	Aug 17, 1982		Mar	CRLD
>A>	AB	+ MYLAN PHARMS INC	5MG	A087672	001	Aug 17, 1982		Mar	CRLD

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

>D>	AP	TEVA PARENTERAL	50MG/ML	A072974	001	Nov 22, 1991		Mar	DISC
>A>		@	50MG/ML	A072974	001	Nov 22, 1991		Mar	DISC

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

	AB	SUN PHARM INDS INC	5MG	A090710	001	Mar 15, 2012		Feb	NEWA
	AB		10MG	A090710	002	Mar 15, 2012		Feb	NEWA
	AB		20MG	A090710	003	Mar 15, 2012		Feb	NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

>D>	AP	TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266	001	Nov 30, 1992	Mar	DISC
>A>		@	EQ 125MG BASE/VIAL	A081266	001	Nov 30, 1992	Mar	DISC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HYDROCHLORIDE

		@ TEVA PARENTERAL	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	Jan	DISC

METRONIDAZOLE

CREAM; TOPICAL
METRONIDAZOLE

	AB	FOUGERA PHARMS	0.75%	A076408	001	May 28, 2004	Jan	CAHN

GEL; TOPICAL
METRONIDAZOLE

	AB	FOUGERA PHARMS	0.75%	A077018	001	Jun 06, 2006	Jan	CAHN

LOTION; TOPICAL
METRONIDAZOLE

	AB	FOUGERA PHARMS	0.75%	A077197	001	May 24, 2006	Jan	CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

	AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A090696	001	Feb 29, 2012	Feb	NEWA
	AP		EQ 5MG BASE/ML	A090850	001	Jan 25, 2012	Jan	NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL
PROAMATINE

	AB	SHIRE LLC	2.5MG	N019815	001	Sep 06, 1996	Jan	CAHN
	AB	+	5MG	N019815	002	Sep 06, 1996	Jan	CAHN
	AB		10MG	N019815	003	Mar 20, 2002	Jan	CAHN

MIFEPRISTONE

TABLET; ORAL
KORLYM

	+	CORCEPT THERAP	300MG	N202107	001	Feb 17, 2012	Feb	NEWA

MITOMYCIN

FOR SOLUTION; TOPICAL
MITOSOL

	+	MOBIUS THERAP	0.2MG/VIAL	N022572	001	Feb 07, 2012	Feb	NEWA

MOMETASONE FUROATE

CREAM; TOPICAL
MOMETASONE FUROATE

	AB	FOUGERA PHARMS	0.1%	A076171	001	Apr 08, 2005	Jan	CAHN

LOTION; TOPICAL
MOMETASONE FUROATE

	AB	FOUGERA PHARMS	0.1%	A075919	001	Nov 29, 2007	Jan	CAHN

OINTMENT; TOPICAL
MOMETASONE FUROATE

	AB	FOUGERA PHARMS	0.1%	A077061	001	Mar 28, 2005	Jan	CAHN

MUPIROCIN

OINTMENT; TOPICAL
MUPIROCIN

AB		FOUGERA PHARMS	2%	A065192	001	Nov 30, 2005	Jan	CAHN

NABUMETONE

TABLET; ORAL
NABUMETONE

AB		PROSAM LABS	500MG	A079093	001	Feb 27, 2009	Feb	CMFD
AB			750MG	A079093	002	Feb 27, 2009	Feb	CMFD

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL
NAFTIN

	+	MERZ PHARMS	2%	N019599	002	Jan 13, 2012	Jan	NEWA

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HYDROCHLORIDE

AB		SUN PHARMA GLOBAL	50MG	A090356	001	Feb 24, 2012	Feb	NEWA

NITROGLYCERIN

OINTMENT; INTRA-ANAL
RECTIV

	+	APTALIS PHARMA	0.4%	N021359	001	Jun 21, 2011	Jan	CAHN

NIZATIDINE

CAPSULE; ORAL
AXID

>D>								
>D>	AB	SMITHKLINE BEECHAM	150MG	N019508	001	Apr 12, 1988	Mar	DISC
>A>		@	150MG	N019508	001	Apr 12, 1988	Mar	DISC
>D>	AB	+	300MG	N019508	002	Apr 12, 1988	Mar	DISC
>A>		@	300MG	N019508	002	Apr 12, 1988	Mar	DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
NOREPINEPHRINE BITARTRATE

>A>	AP	SINTETICA	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	Mar	NEWA

NYSTATIN

CREAM; TOPICAL
NYSTATIN

	AT	FOUGERA PHARMS	100,000 UNITS/GM	A062129	001		Jan	CAHN

OINTMENT; TOPICAL
NYSTATIN

	AT	+ FOUGERA PHARMS	100,000 UNITS/GM	A062124	002	Sep 23, 1982	Jan	CAHN

OLANZAPINE

INJECTABLE; INTRAMUSCULAR
OLANZAPINE

>D>	AP	INNOPHARMA LLC	10MG/VIAL	A201588	001	Oct 24, 2011	Mar	CAHN
>A>	AP	PHARMAFORCE	10MG/VIAL	A201741	001	Mar 20, 2012	Mar	NEWA
>A>	AP	SANDOZ INC	10MG/VIAL	A201588	001	Oct 24, 2011	Mar	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
OLANZAPINE

AB	BARR LABS INC	5MG	A077243	001	Jan 30, 2012	Jan	NEWA
AB		10MG	A077243	002	Jan 30, 2012	Jan	NEWA
AB		15MG	A077243	003	Jan 30, 2012	Jan	NEWA
AB		20MG	A077243	004	Jan 30, 2012	Jan	NEWA
AB	SUN PHARM INDS	5MG	A090881	001	Feb 28, 2012	Feb	NEWA
AB		10MG	A090881	002	Feb 28, 2012	Feb	NEWA
AB		15MG	A090881	003	Feb 28, 2012	Feb	NEWA
AB		20MG	A090881	004	Feb 28, 2012	Feb	NEWA

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL
TAMIFLU

+	ROCHE	EQ 6MG BASE/ML	N021246	002	Mar 21, 2011	Jan	CRLD

OXACILLIN SODIUM

INJECTABLE; INJECTION
OXACILLIN SODIUM

>A> AP	SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246	001	Mar 30, 2012	Mar	NEWA
>A> AP		EQ 2GM BASE/VIAL	A091246	002	Mar 30, 2012	Mar	NEWA
>A> AP		EQ 10GM BASE/VIAL	A091245	001	Mar 30, 2012	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)
OXALIPLATIN

>D> AP	TEVA PARENTERAL	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Mar	CRLD
>D> AP		100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Mar	CRLD
>A> AP +	TEVA PHARMS	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Mar	CRLD
>A> AP +		100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Mar	CRLD

OXICONAZOLE NITRATE

CREAM; TOPICAL
OXISTAT

+	FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988	Jan	CAHN

OXYBUTYNIN

GEL, METERED; TRANSDERMAL
ANTUROL

+	WATSON LABS INC	3%	N202513	001	Dec 07, 2011	Feb	CAHN

OXYBUTYNIN CHLORIDE

TABLET; ORAL

>D>	DITROPAN							
>D> AB +	JANSSEN PHARMS	5MG	N017577	001		Mar	DISC
>A>	@	5MG	N017577	001		Mar	DISC
	OXYBUTYNIN CHLORIDE							
>D> AB	VINTAGE PHARMS	5MG	A075079	001	Oct 31, 1997	Mar	CRLD
>A> AB +		5MG	A075079	001	Oct 31, 1997	Mar	CRLD

TABLET, EXTENDED RELEASE; ORAL
OXYBUTYNIN CHLORIDE

>A> AB	MYLAN PHARMS INC	15MG	A076644	002	May 10, 2007	Mar	NEWA

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

		+	VISTAPHARM	5MG/5ML	N201194	001	Jan 12, 2012	Jan	NEWA

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

		@	TEVA PARENTERAL	10USP UNITS/ML (10USP UNITS/ML)	A077453	001	Jan 24, 2008	Jan	DISC
>D>	AP			100USP UNITS/10ML (10USP UNITS/ML)	A077453	002	Jan 24, 2008	Mar	DISC
>A>		@		100USP UNITS/10ML (10USP UNITS/ML)	A077453	002	Jan 24, 2008	Mar	DISC

PACLITAXEL

INJECTABLE; INJECTION

TAXOL

>D>		@	BRISTOL MYERS SQUIBB	6MG/ML	N020262	001	Dec 29, 1992	Mar	CAHN
>A>		@	CORDEN PHARMA	6MG/ML	N020262	001	Dec 29, 1992	Mar	CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

>D> AREDIA

>D>	AP	+	NOVARTIS	30MG/VIAL	N020036	001	Oct 31, 1991	Mar	DISC
>A>		@		30MG/VIAL	N020036	001	Oct 31, 1991	Mar	DISC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

			ABBOTT LABS	30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725	001	Apr 30, 2009	Feb	CAHN
				60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725	002	Apr 30, 2009	Feb	CAHN
		+		120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725	003	Apr 30, 2009	Feb	CAHN

>A> ULTRESA

>A>			APTALIS PHARMA US	27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222	001	Mar 01, 2012	Mar	NEWA
>A>				41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222	002	Mar 01, 2012	Mar	NEWA
>A>		+		46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222	003	Mar 01, 2012	Mar	NEWA

>A> TABLET; ORAL

>A> VIOKACE

>A>			APTALIS PHARMA US	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Mar	NEWA
>A>		+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Mar	NEWA

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

	AB		MACLEODS PHARMS LTD	EQ 20MG BASE	A200821	001	Feb 16, 2012	Jan	NEWA
	AB			EQ 40MG BASE	A200821	002	Feb 16, 2012	Jan	NEWA

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

	AB		ACTAVIS ELIZABETH	EQ 10MG BASE	A076968	001	Jun 21, 2010	Feb	CMFD

TABLET; ORAL
PAROXETINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	EQ 20MG BASE	A076968	002	Jun 21, 2010	Feb	CMFD
AB			EQ 30MG BASE	A076968	003	Jun 21, 2010	Feb	CMFD
AB			EQ 40MG BASE	A076968	004	Jun 21, 2010	Feb	CMFD

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS
OMONTYS

>A>	+	AFFYMAX	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012	Mar	NEWA
>A>	+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012	Mar	NEWA

OMONTYS PRESERVATIVE FREE

>A>	+	AFFYMAX	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012	Mar	NEWA
>A>	+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012	Mar	NEWA
>A>	+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012	Mar	NEWA
>A>	+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012	Mar	NEWA
>A>	+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012	Mar	NEWA
>A>	+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012	Mar	NEWA

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION
NEMBUTAL SODIUM

	+	OAK PHARMS	50MG/ML	A083246	001		Feb	CAHN

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON

AB		XOMA	2MG	N020184	001	Dec 30, 1993	Jan	CAHN
AB			4MG	N020184	002	Dec 30, 1993	Jan	CAHN
AB	+		8MG	N020184	003	Dec 30, 1993	Jan	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HYDROCHLORIDE

AA		LANNETT	15MG	A087022	002	Jan 20, 2012	Feb	NEWA

TABLET; ORAL
PHENTERMINE HYDROCHLORIDE

	@	SANDOZ INC	30MG	A088605	001	Sep 28, 1987	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL
SUPRENZA

>A>		CITIUS PHARMS	37.5MG	N202088	003	Mar 27, 2012	Mar	NEWA

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL
PHENTERMINE RESIN COMPLEX

	+	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872	001	Jul 28, 2011	Jan	CRLD
	+		EQ 30MG BASE	A040872	002	Jul 28, 2011	Jan	CRLD

PHYTONADIONE

INJECTABLE; INJECTION
PHYTONADIONE

BP	+	INTL MEDICATION	1MG/0.5ML	A083722	001		Feb	CRLD

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

>D>			TAKEDA PHARMS NA	EQ 15MG BASE	N021073	001	Jul 15, 1999	Mar	CAHN
>D>				EQ 30MG BASE	N021073	002	Jul 15, 1999	Mar	CAHN
>D>		+		EQ 45MG BASE	N021073	003	Jul 15, 1999	Mar	CAHN
>A>			TAKEDA PHARMS USA	EQ 15MG BASE	N021073	001	Jul 15, 1999	Mar	CAHN
>A>				EQ 30MG BASE	N021073	002	Jul 15, 1999	Mar	CAHN
>A>		+		EQ 45MG BASE	N021073	003	Jul 15, 1999	Mar	CAHN

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

K+10

>D>	BC		FUTURE PAK	10MEQ	A070999	001	Oct 22, 1987	Mar	DISC
>A>			@	10MEQ	A070999	001	Oct 22, 1987	Mar	DISC

KAON CL-10

>D>	BC		SAVAGE LABS	10MEQ	N017046	002		Mar	DISC
>A>			@	10MEQ	N017046	002		Mar	DISC

KLOR-CON M20

>D>	AB		UPSHER SMITH	20MEQ	A074726	001	Nov 20, 1998	Mar	CRLD
>A>	AB	+	UPSHER-SMITH LABS	20MEQ	A074726	001	Nov 20, 1998	Mar	CRLD

KLOTRIX

>D>	BC		APOTHECON	10MEQ	N017850	001		Mar	DISC
>A>			@	10MEQ	N017850	001		Mar	DISC

POTASSIUM CHLORIDE

>D>	AB		NESHER PHARMS	20MEQ	A076044	001	Apr 05, 2002	Mar	DISC
>A>			@	20MEQ	A076044	001	Apr 05, 2002	Mar	DISC
>D>	AB		SCHERING	10MEQ	N019439	002	Jun 13, 1986	Mar	DISC
>A>			@	10MEQ	N019439	002	Jun 13, 1986	Mar	DISC
>D>	AB	+		20MEQ	N019439	001	Jun 13, 1986	Mar	DISC
>A>			@	20MEQ	N019439	001	Jun 13, 1986	Mar	DISC

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

			@ NOVA K	10MEQ/PACKET	N019647	002	Oct 13, 1988	Feb	CAHN
			@	20MEQ/PACKET	N019647	001	Oct 13, 1988	Feb	CAHN

PREDNICARBATE

CREAM; TOPICAL

PREDNICARBATE

	AB		FOUGERA PHARMS	0.1%	A077287	001	Sep 19, 2006	Jan	CAHN

OINTMENT; TOPICAL

PREDNICARBATE

	AB		FOUGERA PHARMS	0.1%	A077236	001	Mar 09, 2007	Jan	CAHN

PREGABALIN

CAPSULE; ORAL

LYRICA

			PF PRISM	25MG	N021446	001	Dec 30, 2004	Jan	CAHN
				50MG	N021446	002	Dec 30, 2004	Jan	CAHN
				75MG	N021446	003	Dec 30, 2004	Jan	CAHN
				100MG	N021446	004	Dec 30, 2004	Jan	CAHN
				150MG	N021446	005	Dec 30, 2004	Jan	CAHN
				200MG	N021446	006	Dec 30, 2004	Jan	CAHN

		CAPSULE; ORAL						
		LYRICA						
		PF PRISM	225MG	N021446	007	Dec 30, 2004	Jan	CAHN
	+		300MG	N021446	008	Dec 30, 2004	Jan	CAHN
		SOLUTION; ORAL						
		LYRICA						
	+	PF PRISM	20MG/ML	N022488	001	Jan 04, 2010	Jan	CAHN
		PROGESTERONE						
		CAPSULE; ORAL						
		PROGESTERONE						
	AB	TEVA PHARMS	100MG	A202121	001	Feb 29, 2012	Feb	NEWA
	AB		200MG	A202121	002	Feb 29, 2012	Feb	NEWA
		PROMETRIUM						
	AB	ABBOTT LABS	100MG	N019781	001	May 14, 1998	Feb	CFTG
	AB	+	200MG	N019781	002	Oct 15, 1999	Feb	CFTG
		QUETIAPINE FUMARATE						
		TABLET; ORAL						
>A>		QUETIAPINE FUMARATE						
>A>	AB	ACCORD HLTHCARE INC	EQ 25MG BASE	A202152	001	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 50MG BASE	A202152	002	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 100MG BASE	A202152	003	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 200MG BASE	A202152	004	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 300MG BASE	A202152	005	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 400MG BASE	A202152	006	Mar 27, 2012	Mar	NEWA
>A>	AB	APOTEX INC	EQ 25MG BASE	A090960	001	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 50MG BASE	A090960	002	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 100MG BASE	A090960	003	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 200MG BASE	A090960	004	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 300MG BASE	A090960	005	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 400MG BASE	A090960	006	Mar 27, 2012	Mar	NEWA
>A>	AB	AUROBINDO PHARMA LTD	EQ 25MG BASE	A091388	001	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 50MG BASE	A091388	002	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 100MG BASE	A091388	003	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 150MG BASE	A091388	004	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 200MG BASE	A091388	005	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 300MG BASE	A091388	006	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 400MG BASE	A091388	007	Mar 27, 2012	Mar	NEWA
>A>	AB	DR REDDYS LABS LTD	EQ 25MG BASE	A077380	001	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 50MG BASE	A077380	002	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 100MG BASE	A077380	003	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 150MG BASE	A077380	004	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 200MG BASE	A077380	005	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 300MG BASE	A077380	006	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 400MG BASE	A077380	007	Mar 27, 2012	Mar	NEWA
>A>	AB	LUPIN LTD	EQ 25MG BASE	A201109	001	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 50MG BASE	A201109	002	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 100MG BASE	A201109	003	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 200MG BASE	A201109	004	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 300MG BASE	A201109	005	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 400MG BASE	A201109	006	Mar 27, 2012	Mar	NEWA
>A>	AB	MYLAN PHARMS INC	EQ 25MG BASE	A090323	001	Mar 27, 2012	Mar	NEWA
>A>	AB	ROXANE	EQ 25MG BASE	A090120	001	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 50MG BASE	A090749	001	Mar 27, 2012	Mar	NEWA
>A>	AB		EQ 100MG BASE	A090749	002	Mar 27, 2012	Mar	NEWA

TABLET; ORAL

>A>			QUETIAPINE FUMARATE						
>A>	AB		ROXANE	EQ 200MG BASE	A090749	003	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 300MG BASE	A090749	004	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 400MG BASE	A090749	005	Mar 27, 2012	Mar	NEWA
>A>	AB		SUN PHARMA GLOBAL	EQ 25MG BASE	A201190	001	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 50MG BASE	A201190	002	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 100MG BASE	A201190	003	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 200MG BASE	A201190	004	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 300MG BASE	A201190	005	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 400MG BASE	A201190	006	Mar 27, 2012	Mar	NEWA
>A>	AB		TEVA PHARMS	EQ 25MG BASE	A077745	001	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 50MG BASE	A077745	002	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 100MG BASE	A077745	003	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 150MG BASE	A077745	004	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 200MG BASE	A077745	005	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 300MG BASE	A077745	006	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 400MG BASE	A077745	007	Mar 27, 2012	Mar	NEWA
>A>	AB		TORRENT PHARMS LTD	EQ 25MG BASE	A200363	001	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 50MG BASE	A200363	002	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 100MG BASE	A200363	003	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 200MG BASE	A200363	004	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 300MG BASE	A200363	005	Mar 27, 2012	Mar	NEWA
>A>	AB			EQ 400MG BASE	A200363	006	Mar 27, 2012	Mar	NEWA
			SEROQUEL						
>D>		+	ASTRAZENECA	EQ 25MG BASE	N020639	001	Sep 26, 1997	Mar	CFTG
>A>	AB	+		EQ 25MG BASE	N020639	001	Sep 26, 1997	Mar	CFTG
>D>				EQ 50MG BASE	N020639	007	Oct 04, 2005	Mar	CFTG
>A>	AB			EQ 50MG BASE	N020639	007	Oct 04, 2005	Mar	CFTG
>D>				EQ 100MG BASE	N020639	002	Sep 26, 1997	Mar	CFTG
>A>	AB			EQ 100MG BASE	N020639	002	Sep 26, 1997	Mar	CFTG
>D>				EQ 200MG BASE	N020639	003	Sep 26, 1997	Mar	CFTG
>A>	AB			EQ 200MG BASE	N020639	003	Sep 26, 1997	Mar	CFTG
>D>		+		EQ 300MG BASE	N020639	005	Jul 26, 2000	Mar	CFTG
>A>	AB	+		EQ 300MG BASE	N020639	005	Jul 26, 2000	Mar	CFTG
>D>				EQ 400MG BASE	N020639	006	Oct 04, 2005	Mar	CFTG
>A>	AB			EQ 400MG BASE	N020639	006	Oct 04, 2005	Mar	CFTG

RAMIPRIL

TABLET; ORAL

			ALTACE						
			@ KING PFIZER	1.25MG	N022021	001	Feb 27, 2007	Jan	DISC
			@	2.5MG	N022021	002	Feb 27, 2007	Jan	DISC
			@	5MG	N022021	003	Feb 27, 2007	Jan	DISC
			@	10MG	N022021	004	Feb 27, 2007	Jan	DISC

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

			ZANTAC						
>A>	AP	+	COVIS PHARMA	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Mar	CAHN
>D>	AP	+	GLAXOSMITHKLINE	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Mar	CAHN
			ZANTAC IN PLASTIC CONTAINER						
>A>		+	COVIS PHARMA	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Mar	CAHN
>A>			@	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Mar	CAHN
>D>		+	GLAXOSMITHKLINE	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Mar	CAHN
>D>			@	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Mar	CAHN

RIFAMPIN

CAPSULE; ORAL
RIMACTANE

AB	PROSAM LABS	300MG	N050429	001		Feb	CMFD

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL
EDURANT

+	JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011	Feb	CAHN

RISPERIDONE

TABLET; ORAL
RISPERIDONE

AB	PROSAM LABS	0.25MG	A078071	001	Jun 17, 2009	Feb	CMFD
AB		0.5MG	A078071	002	Jun 17, 2009	Feb	CMFD
AB		1MG	A078071	003	Jun 17, 2009	Feb	CMFD
AB		2MG	A078071	004	Jun 17, 2009	Feb	CMFD
AB		3MG	A078071	005	Jun 17, 2009	Feb	CMFD
AB		4MG	A078071	006	Jun 17, 2009	Feb	CMFD

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERIDONE

AB	TEVA	0.5MG	A076908	001	Mar 12, 2012	Feb	NEWA
AB		1MG	A076908	002	Mar 12, 2012	Feb	NEWA
AB		2MG	A076908	003	Mar 12, 2012	Feb	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL
ROPINIROLE HYDROCHLORIDE

AB	APOTEX	EQ 0.25MG BASE	A079165	001	Feb 07, 2012	Jan	NEWA
AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012	Jan	NEWA
AB		EQ 1MG BASE	A079165	003	Feb 07, 2012	Jan	NEWA
AB		EQ 2MG BASE	A079165	004	Feb 07, 2012	Jan	NEWA
AB		EQ 3MG BASE	A079165	005	Feb 07, 2012	Jan	NEWA
AB		EQ 4MG BASE	A079165	006	Feb 07, 2012	Jan	NEWA
AB		EQ 5MG BASE	A079165	007	Feb 07, 2012	Jan	NEWA

SERTACONAZOLE NITRATE

CREAM; TOPICAL
ERTACZO

+	VALEANT INTL	2%	N021385	001	Dec 10, 2003	Jan	CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL
SERTRALINE HYDROCHLORIDE

AB	PROSAM LABS	EQ 25MG BASE	A078175	001	Jul 21, 2010	Feb	CMFD
AB		EQ 50MG BASE	A078175	002	Jul 21, 2010	Feb	CMFD
AB		EQ 100MG BASE	A078175	003	Jul 21, 2010	Feb	CMFD

SIMVASTATIN

TABLET; ORAL
SIMVASTATIN

AB	PROSAM LABS	5MG	A078735	001	Aug 30, 2010	Feb	CMFD
AB		10MG	A078735	002	Aug 30, 2010	Feb	CMFD
AB		20MG	A078735	003	Aug 30, 2010	Feb	CMFD
AB		40MG	A078735	004	Aug 30, 2010	Feb	CMFD

TABLET; ORAL
SIMVASTATIN
AB PROSAM LABS 80MG A078735 005 Aug 30, 2010 Feb CMFD

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL
BAROS
@ MALLINCKRODT INC 460MG/GM;420MG/GM N018509 001 Aug 07, 1985 Jan CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9%
AP HIKMA (MAPLE) 9MG/ML A201850 001 Jan 20, 2012 Jan NEWA
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
MEDEFIL 9MG/ML N202832 001 Jan 06, 2012 Jan NEWA

SODIUM IODIDE I-131

CAPSULE; ORAL
SODIUM IODIDE I-131
JUBILANT DRAXIMAGE 9-100mCi N021305 006 May 19, 2005 Feb CAHN
@ 2-200mCi N021305 004 Nov 18, 2004 Jan DISC
SOLUTION; ORAL
HICON
@ JUBILANT DRAXIMAGE 1-500mCi/0.5ML N021305 003 Jan 24, 2003 Feb DISC
@ 1-250mCi/0.25ML N021305 002 Jan 24, 2003 Feb DISC
@ 1-1000mCi/ML N021305 005 Apr 04, 2006 Feb DISC
+ 250-1000mCi N021305 007 Dec 05, 2011 Jan NEWA

SODIUM NITRITE

SOLUTION; INTRAVENOUS
SODIUM NITRITE
+ HOPE PHARMS 300MG/10ML (30MG/ML) N203922 001 Feb 14, 2012 Feb NEWA

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS
SODIUM THIOSULFATE
+ HOPE PHARMS 12.5GM/50ML (250MG/ML) N203923 001 Feb 14, 2012 Feb NEWA

SUCCIMER

CAPSULE; ORAL
CHEMET
>D> + LUNDBECK INC 100MG N019998 002 Jan 30, 1991 Mar CAHN
>A> + LUNDBECK LLC 100MG N019998 002 Jan 30, 1991 Mar CAHN

SULFACETAMIDE SODIUM

LOTION; TOPICAL
SULFACETAMIDE SODIUM
AB FOUGERA PHARMS 10% A077015 001 Nov 17, 2006 Jan CAHN

SULFANILAMIDE

CREAM; VAGINAL
AVC
>D> + AZUR PHARMA 15% N006530 003 Jan 27, 1987 Mar CAHN
>A> + JAZZ PHARMS COMMERCL 15% N006530 003 Jan 27, 1987 Mar CAHN

SUPPOSITORY; VAGINAL
AVC

>D>		@ AZUR PHARMA	1.05GM	N006530	004	Jan 27, 1987	Mar	CAHN
>A>		@ JAZZ PHARMS COMMERCL	1.05GM	N006530	004	Jan 27, 1987	Mar	CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

>D>	AP	BEDFORD LABS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310	001	Aug 11, 2010	Mar	CAHN
>A>	AP	INJECTALIA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310	001	Aug 11, 2010	Mar	CAHN

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC
ZIOPTAN

	+	MERCK SHARP DOHME	0.0015%	N202514	001	Feb 10, 2012	Feb	NEWA

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL
VIREAD

	+	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577	001	Jan 18, 2012	Jan	NEWA

TERBUTALINE SULFATE

INJECTABLE; INJECTION
TERBUTALINE SULFATE

		@ TEVA PARENTERAL	1MG/ML	A076853	001	Jul 20, 2004	Jan	DISC

TERCONAZOLE

CREAM; VAGINAL
TERCONAZOLE

AB		FOUGERA PHARMS	0.4%	A076712	001	Feb 18, 2005	Jan	CAHN

SUPPOSITORY; VAGINAL
TERCONAZOLE

AB		FOUGERA PHARMS	80MG	A076850	001	Jul 12, 2006	Jan	CAHN

TESTOSTERONE

GEL; TRANSDERMAL
ANDROGEL

		ABBOTT LABS	1% (25MG/2.5GM PACKET)	N021015	001	Feb 28, 2000	Feb	CPOT
BX	+		1% (50MG/5GM PACKET)	N021015	002	Feb 28, 2000	Feb	CPOT

TESTIM

BX	+	AUXILIUM PHARMS	1% (50MG/5GM PACKET)	N021454	001	Oct 31, 2002	Feb	CPOT

TESTOSTERONE

		TEVA PHARMS	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	Feb	NEWA
			50MG/5GM PACKET	N202763	002	Feb 14, 2012	Feb	NEWA

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION
TESTOSTERONE CYPIONATE

AO		MYLAN INSTITUTIONAL	200MG/ML	A040652	001	Dec 11, 2006	Feb	CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
TESTOSTERONE ENANTHATE

AO		MYLAN INSTITUTIONAL	200MG/ML	A040647	001	Oct 05, 2009	Feb	CAHN

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

		+	FOUGERA PHARMS	0.05%	A086576	002		Jan	CAHN
				0.1%	A086576	001		Jan	CAHN

SPRAY; NASAL

TYZINE

		+	FOUGERA PHARMS	0.1%	A086576	003		Jan	CAHN

THEOPHYLLINE

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP	+	BAXTER HLTHCARE	4MG/ML	N018649	007	Jul 26, 1982	Mar	DISC
>A>		@		4MG/ML	N018649	007	Jul 26, 1982	Mar	DISC
>D>	AP	+		40MG/100ML	N018649	001	Jul 26, 1982	Mar	DISC
>A>		@		40MG/100ML	N018649	001	Jul 26, 1982	Mar	DISC
>D>	AP	+		80MG/100ML	N018649	002	Jul 26, 1982	Mar	DISC
>A>		@		80MG/100ML	N018649	002	Jul 26, 1982	Mar	DISC
>D>	AP	+		160MG/100ML	N018649	003	Jul 26, 1982	Mar	DISC
>A>		@		160MG/100ML	N018649	003	Jul 26, 1982	Mar	DISC
>D>	AP	+		200MG/100ML	N018649	004	Jul 26, 1982	Mar	DISC
>A>		@		200MG/100ML	N018649	004	Jul 26, 1982	Mar	DISC
>D>	AP	+		320MG/100ML	N018649	006	Nov 13, 1985	Mar	DISC
>A>		@		320MG/100ML	N018649	006	Nov 13, 1985	Mar	DISC
>D>	AP	+		400MG/100ML	N018649	005	Jul 26, 1982	Mar	DISC
>A>		@		400MG/100ML	N018649	005	Jul 26, 1982	Mar	DISC

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

		@	CEPHALON	6MG	N020646	006	Nov 29, 2005	Jan	DISC
		@		8MG	N020646	007	Nov 29, 2005	Jan	DISC
		@		10MG	N020646	008	Nov 29, 2005	Jan	DISC

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

	AB		APOTEX INC	EQ 2MG BASE	A078868	001	Feb 03, 2012	Jan	NEWA
	AB			EQ 4MG BASE	A078868	002	Feb 03, 2012	Jan	NEWA
	AB			EQ 6MG BASE	A078868	003	Feb 03, 2012	Jan	NEWA

ZANAFLEX

	AB		ACORDA	EQ 2MG BASE	N021447	001	Aug 29, 2002	Jan	CFTG
	AB			EQ 4MG BASE	N021447	002	Aug 29, 2002	Jan	CFTG
	AB	+		EQ 6MG BASE	N021447	003	Aug 29, 2002	Jan	CFTG

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

	AB		PROSAM LABS	EQ 2MG BASE	A076281	001	Oct 20, 2003	Feb	CMFD
	AB			EQ 4MG BASE	A076281	002	Oct 20, 2003	Feb	CMFD
	AB		SANDOZ INC	EQ 2MG BASE	A076280	001	Nov 26, 2002	Feb	NEWA

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

>D>	AB		MYLAN	500MG	A086445	001		Mar	CRLD
>A>		+	MYLAN PHARMS INC	500MG	A086445	001		Mar	CRLD

TABLET; ORAL
TOLBUTAMIDE

>D>	AB		WATSON LABS	500MG	A087318	001	Mar	DISC
>D>	AB	+		500MG	A086109	001	Mar	DISC
>A>		@		500MG	A087318	001	Mar	DISC
>A>		@		500MG	A086109	001	Mar	DISC

TRAMADOL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL
RYBIX ODT

>A>		+	SHIONOGI INC	50MG	N021693	001 May 05, 2005	Mar	CTNA

TRAMADOL HYDROCHLORIDE

>D>		+	SHIONOGI INC	50MG	N021693	001 May 05, 2005	Mar	CTNA

TRANEXAMIC ACID

INJECTABLE; INJECTION
TRANEXAMIC ACID

	AP		NEXUS PHARMS	100MG/ML	A091596	001 Mar 02, 2012	Feb	NEWA

TRANYLCYPROMINE SULFATE

TABLET; ORAL
PARNATE

	AB	+	COVIS PHARMA	EQ 10MG BASE	N012342	003 Aug 16, 1985	Jan	CAHN

TRETINOIN

CREAM; TOPICAL
RENOVA

		+	VALEANT INTL	0.02%	N021108	001 Aug 31, 2000	Jan	CAHN
	AB2	+		0.05%	N019963	001 Dec 29, 1995	Jan	CAHN

RETIN-A

	AB	+	VALEANT INTL	0.025%	N019049	001 Sep 16, 1988	Jan	CAHN
	AB1	+		0.05%	N017522	001	Jan	CAHN
	AB	+		0.1%	N017340	001	Jan	CAHN

GEL; TOPICAL
RETIN-A

	AB	+	VALEANT INTL	0.01%	N017955	001	Jan	CAHN
	AB	+		0.025%	N017579	002	Jan	CAHN

SOLUTION; TOPICAL
RETIN-A

	AT	+	VALEANT INTL	0.05%	N016921	001	Jan	CAHN

SWAB; TOPICAL
RETIN-A

		@	VALEANT INTL	0.05%	N016921	002	Jan	CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

	AT		FOUGERA PHARMS	0.025%	A085692	001	Jan	CAHN
	AT			0.1%	A085692	003	Jan	CAHN
	AT	+		0.5%	A085692	002	Jan	CAHN

LOTION; TOPICAL
TRIAMCINOLONE ACETONIDE

	AT		FOUGERA PHARMS	0.025%	A040467	001 Apr 21, 2003	Jan	CAHN
	AT			0.1%	A040467	002 Apr 21, 2003	Jan	CAHN

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE

AT		FOUGERA PHARMS	0.025%	A085691	001		Jan	CAHN
AT			0.1%	A085691	003		Jan	CAHN
AT			0.5%	A085691	002		Jan	CAHN

SPRAY, METERED; NASAL
TRIAMCINOLONE ACETONIDE

>D>	AB	TEVA BRANDED PHARM	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Mar	CAHN
>A>	AB	TEVA PHARMS	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Mar	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALACYCLOVIR HYDROCHLORIDE

>A>	AB	JUBILANT ORGANOSYS	EQ 500MG BASE	A201506	001	Apr 03, 2012	Mar	NEWA
>A>	AB		EQ 1GM BASE	A201506	002	Apr 03, 2012	Mar	NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL
VANCOCIN HYDROCHLORIDE

>D>		VIROPHARMA	EQ 125MG BASE	N050606	001	Apr 15, 1986	Mar	CFTG
>A>	AB		EQ 125MG BASE	N050606	001	Apr 15, 1986	Mar	CFTG
>D>	+		EQ 250MG BASE	N050606	002	Apr 15, 1986	Mar	CFTG
>A>	AB +		EQ 250MG BASE	N050606	002	Apr 15, 1986	Mar	CFTG

>A> VANCOMYCIN HYDROCHLORIDE

>A>	AB	AKORN	EQ 125MG BASE	A065478	001	Apr 09, 2012	Mar	NEWA
>A>	AB		EQ 250MG BASE	A065478	002	Apr 09, 2012	Mar	NEWA
>A>	AB	STRIDES ARCOLAB LTD	EQ 125MG BASE	A065490	001	Apr 09, 2012	Mar	NEWA
>A>	AB		EQ 250MG BASE	A065490	002	Apr 09, 2012	Mar	NEWA
>A>	AB	WATSON LABS	EQ 125MG BASE	A065510	001	Apr 09, 2012	Mar	NEWA
>A>	AB		EQ 250MG BASE	A065510	002	Apr 09, 2012	Mar	NEWA

VANDETANIB

TABLET; ORAL
CAPRELSA

		IPR PHARMS INC	100MG	N022405	001	Apr 06, 2011	Feb	CTNA
	+		300MG	N022405	002	Apr 06, 2011	Feb	CTNA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VENLAFAXINE HYDROCHLORIDE

>A>	AB	ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012	Mar	NEWA
>A>	AB		EQ 75MG BASE	A078087	002	Mar 16, 2012	Mar	NEWA
>A>	AB		EQ 150MG BASE	A078087	003	Mar 16, 2012	Mar	NEWA

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
CALAN SR

AB	+	PFIZER	120MG	N019152	003	Mar 06, 1991	Feb	CTNA
AB	+		180MG	N019152	002	Dec 15, 1989	Feb	CTNA
AB	+		240MG	N019152	001	Dec 16, 1986	Feb	CTNA

VISMODEGIB

CAPSULE; ORAL
ERIVEDGE

	+	GENENTECH	150MG	N203388	001	Jan 30, 2012	Jan	NEWA

VORICONAZOLE

TABLET; ORAL
VORICONAZOLE

>A>	AB	TEVA PHARMS	50MG	A091658	001	Apr 06, 2012	Mar	NEWA
>A>	AB		200MG	A091658	002	Apr 06, 2012	Mar	NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL
PRIALT

>D>		@ AZUR PHARMA II	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Mar	CAHN
>A>		@ JAZZ PHARMS COMMERCL	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Mar	CAHN

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL
PRIALT

>D>	+	AZUR PHARMA II	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Mar	CAHN
>D>	+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Mar	CAHN
>D>	+		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Mar	CAHN
>A>	+	JAZZ PHARMS COMMERCL	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Mar	CAHN
>A>	+		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Mar	CAHN
>A>	+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Mar	CAHN

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL
GEODON

AB	+	PFIZER	EQ 20MG BASE	N020825	001	Feb 05, 2001	Feb	CFTG
AB			EQ 40MG BASE	N020825	002	Feb 05, 2001	Feb	CFTG
AB			EQ 60MG BASE	N020825	003	Feb 05, 2001	Feb	CFTG
AB			EQ 80MG BASE	N020825	004	Feb 05, 2001	Feb	CFTG

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX CORP	EQ 20MG BASE	A077561	001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077561	002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077561	003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077561	004	Mar 02, 2012	Feb	NEWA
AB		DR REDDYS LABS INC	EQ 20MG BASE	A077565	001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077565	002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077565	003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077565	004	Mar 02, 2012	Feb	NEWA
AB		LUPIN PHARMS	EQ 20MG BASE	A077560	001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077560	002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077560	003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077560	004	Mar 02, 2012	Feb	NEWA

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

PEPCID COMPLETE

>A>	+	MCNEIL CONS	800MG;10MG;165MG	N020958	001	Oct 16, 2000	Mar	CAHN
>D>	+	MERCK SHARP DOHME	800MG;10MG;165MG	N020958	001	Oct 16, 2000	Mar	CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORASCRUB MAXI SWABSTICK

>D>	+	3M INFECTION	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar	CAHN
>A>	+	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar	CAHN

CHLORASCRUB SWAB

>D>	+	3M INFECTION	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar	CAHN
>A>	+	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar	CAHN

CHLORASCRUB SWABSTICK

>D>	+	3M INFECTION	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar	CAHN
>A>	+	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

		STRIDES ARCOLAB LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888	001	Mar 05, 2012	Feb	NEWA

FAMOTIDINE

TABLET, CHEWABLE; ORAL

PEPCID AC

>A>	@	MCNEIL CONS	10MG	N020801	001	Sep 24, 1998	Mar	CAHN
>A>	+		20MG	N020801	002	Dec 17, 2007	Mar	CAHN
>D>	@	MERCK SHARP DOHME	10MG	N020801	001	Sep 24, 1998	Mar	CAHN
>D>	+		20MG	N020801	002	Dec 17, 2007	Mar	CAHN

TABLET; ORAL

PEPCID AC

>A>		MCNEIL CONS	10MG	N020325	001	Apr 28, 1995	Mar	CAHN
>A>	+		20MG	N020325	002	Sep 23, 2003	Mar	CAHN
>D>		MERCK SHARP DOHME	10MG	N020325	001	Apr 28, 1995	Mar	CAHN
>D>	+		20MG	N020325	002	Sep 23, 2003	Mar	CAHN

PEPCID AC (GELTAB)

>A>		MCNEIL CONS	10MG	N020902	001	Aug 05, 1999	Mar	CAHN
>D>		MERCK SHARP DOHME	10MG	N020902	001	Aug 05, 1999	Mar	CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

		SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012	Jan	NEWA
		WOCKHARDT LTD	30MG	A079112	002	Feb 08, 2012	Jan	NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

		SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012	Jan	NEWA
		WOCKHARDT LTD	30MG	A079112	001	Feb 08, 2012	Jan	NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

		SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012	Jan	NEWA
			180MG	A091567	006	Feb 06, 2012	Jan	NEWA
		WOCKHARDT LTD	60MG	A079112	004	Feb 08, 2012	Jan	NEWA

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY

WOCKHARDT LTD	180MG	A079112	006	Feb 08, 2012	Jan NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012	Jan NEWA
	180MG	A091567	005	Feb 06, 2012	Jan NEWA
WOCKHARDT LTD	60MG	A079112	003	Feb 08, 2012	Jan NEWA
	180MG	A079112	005	Feb 08, 2012	Jan NEWA

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

ACCUCAPS INDS	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009	Jan CAHN

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

SHASUN CHEMS	EQ 75MG BASE	A201745	001	Feb 29, 2012	Feb NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 03 MARCH 2012

NO MARCH 2012 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MARCH 2012 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACETYLCYSTEINE - ACETADOTE							
N021539 001	>A>	8148356	May 21, 2026	DP			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO							
N022320 001		8105618	Dec 23, 2022	U-1078			
	>A>	8129362	Jul 18, 2027	U-1078			
ALBUTEROL SULFATE - PROAIR HFA							
N021457 001		6446627	Dec 18, 2017	DP			
	>A>	8132712	Sep 07, 2028	DP			
ALVIMOPAN - ENTEREG							
N021775 001		8112290	Jul 31, 2030	U-1225			
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N022314 001		8101599	May 16, 2023	DP			
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N022314 002		8101599	May 16, 2023	DP			
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N022314 003		8101599	May 16, 2023	DP			
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N022314 004		8101599	May 16, 2023	DP			
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N022314 005		8101599	May 16, 2023	DP			
ARFORMOTEROL TARTRATE - BROVANA							
N021912 001	>A>	6589508	Apr 03, 2013	U-793			
		8110706	Nov 09, 2021	DP			
ATOVAQUONE; PROGUANIL HYDROCHLORIDE - ATOVAQUONE AND PROGUANIL HYDROCHLORIDE							
A091211 001						PC	Mar 13, 2012
AXITINIB - INLYTA							
N202324 001		6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
		7141581	Jun 30, 2020	U-1220			
AXITINIB - INLYTA							
N202324 002		6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
		7141581	Jun 30, 2020	U-1220			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR							
N202331 001		5583141	Dec 10, 2013	DS DP U-3			
		5736555	Jun 25, 2012	DS DP U-3			
		7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP U-3			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR							
N202331 002		5583141	Dec 10, 2013	DS DP U-3			
		5736555	Jun 25, 2012	DS DP U-3			
		7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP U-3			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BALSALAZIDE DISODIUM - GIAZO							
N022205	001	6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
		7452872	Aug 24, 2026	U-1229			
		7625884	Aug 24, 2026	U-1229			
BECLOMETHASONE DIPROPIONATE - QNASL							
N202813	001	**>A>** 5605674	Feb 25, 2014	DP		**>A>** NP	Mar 23, 2015
		>A> 5683677	Nov 04, 2014	DP			
		>A> 5776432	Jul 07, 2015	DP			
		>A> 7780038	Jan 24, 2027	DP			
BIVALIRUDIN - ANGIOMAX							
N020873	001	**>A>** 5196404	Dec 15, 2014	DS DP U-1232			
		>A> 5196404	Dec 15, 2014	DS DP U-1040			
		>A> 5196404*PED	Jun 15, 2015				
BOCEPREVIR - VICTRELIS							
N202258	001	**>A>** 8119602	Mar 17, 2027	U-1233			
BORTEZOMIB - VELCADE							
N021602	001					NR	Jan 23, 2015
BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN							
N021398	001	**>A>** 8133890	Apr 19, 2022	U-1235			
BUPIVACAINE - EXPAREL							
N022496	001	6132766	Nov 16, 2013	DP			
BUPIVACAINE - EXPAREL							
N022496	002	6132766	Nov 16, 2013	DP			
CARVEDILOL PHOSPHATE - COREG CR							
N022012	001	8101209	Sep 11, 2025	DP			
		8101209*PED	Mar 11, 2026				
CARVEDILOL PHOSPHATE - COREG CR							
N022012	002	8101209	Sep 11, 2025	DP			
		8101209*PED	Mar 11, 2026				
CARVEDILOL PHOSPHATE - COREG CR							
N022012	003	8101209	Sep 11, 2025	DP			
		8101209*PED	Mar 11, 2026				
CARVEDILOL PHOSPHATE - COREG CR							
N022012	004	8101209	Sep 11, 2025	DP			
		8101209*PED	Mar 11, 2026				
CICLESONIDE - ZETONNA							
N202129	001	5482934	Oct 24, 2017	DS DP U-1002		NP	Jan 20, 2015
		5605674	Feb 25, 2014	DP			
		5683677	Nov 04, 2014	DP			
		5775321	Jul 07, 2015	DP			
		6006745	Dec 28, 2016	DP			
		6036942	Apr 30, 2013	DP			
		6120752	May 13, 2018	DP			
		6264923	May 13, 2018	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CLEVIDIPINE BUTYRATE - CLEVIPREX							
N022156 001	**>A>**	5856346	Jan 05, 2021	DS DP U-893			
CLEVIDIPINE BUTYRATE - CLEVIPREX							
N022156 002	**>A>**	5856346	Jan 05, 2021	DS DP U-893			
COLCHICINE - COLCRYS							
N022352 001		7964648	Oct 06, 2028	U-1161			
		8097655	Oct 06, 2028	U-1020			
DAPTOMYCIN - CUBICIN							
N021572 002		8129342	Nov 28, 2020	DS DP			
DARUNAVIR ETHANOLATE - PREZISTA							
N021976 001		5843946*PED	Jun 01, 2016				
		6037157	Jun 26, 2016	U-935			
		6037157	Jun 26, 2016	U-1209			
		6037157*PED	Dec 26, 2016				
		6335460	Aug 25, 2012	DS DP U-935			
		6335460	Aug 25, 2012	DS DP U-903			
		6335460	Aug 25, 2012	DS DP U-744			
		6335460	Aug 25, 2012	DS DP U-1209			
		6335460*PED	Feb 25, 2013				
		6703403	Jun 26, 2016	U-935			
		6703403	Jun 26, 2016	U-1209			
		6703403*PED	Dec 26, 2016				
		7470506	Jun 23, 2019	U-935			
		7470506	Jun 23, 2019	U-1209			
		7470506*PED	Dec 23, 2019				
DARUNAVIR ETHANOLATE - PREZISTA							
N021976 002		5843946*PED	Jun 01, 2016				
		6037157	Jun 26, 2016	U-935			
		6037157	Jun 26, 2016	U-1209			
		6037157*PED	Dec 26, 2016				
		6335460	Aug 25, 2012	DS DP U-935			
		6335460	Aug 25, 2012	DS DP U-903			
		6335460	Aug 25, 2012	DS DP U-744			
		6335460	Aug 25, 2012	DS DP U-1209			
		6335460*PED	Feb 25, 2013				
		6703403	Jun 26, 2016	U-935			
		6703403	Jun 26, 2016	U-1209			
		6703403*PED	Dec 26, 2016				
		7470506	Jun 23, 2019	U-935			
		7470506	Jun 23, 2019	U-1209			
		7470506*PED	Dec 23, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 003	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 004	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 005	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N202895 001	5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
DEGARELIX ACETATE - FIRMAGON						
N022201 001	**>A>** 5925730	May 18, 2021	DS DP U-943			
DEGARELIX ACETATE - FIRMAGON						
N022201 002	**>A>** 5925730	May 18, 2021	DS DP U-943			
DEXAMETHASONE - OZURDEX						
N022315 001	8088407	Oct 20, 2020	DP U-1205			
DEXLANSOPRAZOLE - DEXILANT						
N022287 001	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
DEXLANSOPRAZOLE - DEXILANT						
N022287 002	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
DICLOFENAC POTASSIUM - CAMBIA						
N022165 001	8097651	Jun 16, 2026	DS DP U-436			
DICLOFENAC POTASSIUM - ZIPSOR						
N022202 001	8110606	Feb 24, 2029	U-980			
DIENOGEST; ESTRADIOL VALERATE - NATAZIA						
N022252 001					**>A>** I-648	Mar 14, 2015
DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF						
N202667 001					NP	Feb 01, 2015
DROSPIRENONE; ETHINYL ESTRADIOL - ANGELIQ						
N021355 001					NS	Mar 01, 2015
EPROSARTAN MESYLATE - EPROSARTAN MESYLATE						
A202012 001					PC	Jun 17, 2012
EPROSARTAN MESYLATE - EPROSARTAN MESYLATE						
A202012 002					PC	Jun 17, 2012
ERIBULIN MESYLATE - HALAVEN						
N201532 001	8097648	Jan 22, 2021	U-1096			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE						
A076765 001					**>A>** PC	Sep 10, 2012
ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE						
A076765 002					**>A>** PC	Sep 10, 2012
ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE						
A076765 003					**>A>** PC	Sep 10, 2012
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N021957 001	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N021957 002	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
ETRAVIRINE - INTELENCE						
N022187 001					**>A>** NPP	Mar 26, 2015
ETRAVIRINE - INTELENCE						
N022187 002					**>A>** NPP	Mar 26, 2015
ETRAVIRINE - INTELENCE						
N022187 003					**>A>** NPP	Mar 26, 2015
					>A> NCE	Jan 18, 2013
EXENATIDE SYNTHETIC - BYDUREON						
N022200 001	5424286	Dec 01, 2016	U-1108		NP	Jan 27, 2015
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
EXENATIDE SYNTHETIC - BYETTA						
N021773 001					**>A>** M-113	Oct 19, 2014
					M-111	Oct 19, 2014
EXENATIDE SYNTHETIC - BYETTA						
N021773 002					**>A>** M-113	Oct 19, 2014
					M-111	Oct 19, 2014
EZETIMIBE - ZETIA						
N021445 001					M-109	Jan 24, 2015
EZETIMIBE; SIMVASTATIN - VYTORIN						
N021687 001					M-109	Jan 24, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EZETIMIBE; SIMVASTATIN - VYTORIN						
N021687 002					M-109	Jan 24, 2015
EZETIMIBE; SIMVASTATIN - VYTORIN						
N021687 003					M-109	Jan 24, 2015
EZETIMIBE; SIMVASTATIN - VYTORIN						
N021687 004					M-109	Jan 24, 2015
FAMCICLOVIR - FAMVIR						
N020363 001					M-112	Feb 09, 2015
FAMCICLOVIR - FAMVIR						
N020363 002					M-112	Feb 09, 2015
FAMCICLOVIR - FAMVIR						
N020363 003					M-112	Feb 09, 2015
FENOFIBRATE - FENOGLIDE						
N022118 001	**>A>** 8124125	Oct 01, 2024	DP U-1234			
FENOFIBRATE - FENOGLIDE						
N022118 002	**>A>** 8124125	Oct 01, 2024	DP U-1234			
FENTANYL - SUBSYS						
N202788 001					NP	Jan 04, 2015
FENTANYL - SUBSYS						
N202788 002					NP	Jan 04, 2015
FENTANYL - SUBSYS						
N202788 003					NP	Jan 04, 2015
FENTANYL - SUBSYS						
N202788 004					NP	Jan 04, 2015
FENTANYL - SUBSYS						
N202788 005					NP	Jan 04, 2015
FENTANYL CITRATE - FENTORA						
N021947 001	8092832	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA						
N021947 002	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA						
N021947 003	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA						
N021947 004	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA						
N021947 005	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
FESOTERODINE FUMARATE - TOVIAZ						
N022030 001	8088398	Jun 07, 2027	DP U-913			
FESOTERODINE FUMARATE - TOVIAZ						
N022030 002	8088398	Jun 07, 2027	DP U-913			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUNISOLIDE - AEROSPAN HFA							
N021247 001		5776433	Jul 07, 2015	DP			
		5980867	Jul 06, 2018	DP			
FOSPROPOFOL DISODIUM - LUSEDRA							
N022244 001	**>A>**	6204257	Jul 01, 2022	DS DP U-945			
GABAPENTIN ENACARBIL - HORIZANT							
N022399 001		8114909	Apr 11, 2026	U-1231			
GABAPENTIN ENACARBIL - HORIZANT							
N022399 002		8114909	Apr 11, 2026	U-1231			
GADOFOSVESET TRISODIUM - ABLAVAR							
N021711 001	**>A>**	6676929	May 04, 2020	DP			
GADOFOSVESET TRISODIUM - ABLAVAR							
N021711 002	**>A>**	6676929	May 04, 2020	DP			
GLYCOPYRROLATE - CUVPOSA							
N022571 001						ODE	Jul 28, 2017
IMATINIB MESYLATE - GLEEVEC							
N021588 001						ODE	Dec 19, 2015
IMATINIB MESYLATE - GLEEVEC							
N021588 002						ODE	Dec 19, 2015
INGENOL MEBUTATE - PICATO							
N202833 001		6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
		6844013	Aug 19, 2018	DS DP U-1221			
		7410656	Aug 19, 2018	DS U-1222			
INGENOL MEBUTATE - PICATO							
N202833 002		6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
		6844013	Aug 19, 2018	DS DP U-1221			
		7410656	Aug 19, 2018	DS U-1222			
IOFLUPANE I-123 - DATSCAN							
N022454 001	**>A>**	5310912	Feb 25, 2013	DS			
IVACAFTOR - KALYDECO							
N203188 001		7495103	May 20, 2027	DS DP		NCE	Jan 31, 2017
						ODE	Jan 31, 2019
IVERMECTIN - SKLICE							
N202736 001		6103248	May 22, 2018	DP		NP	Feb 07, 2015
IXABEPILONE - IXEMPRA KIT							
N022065 001		RE41911	Sep 28, 2020	DS DP U-961			
		RE41911*PED	Mar 28, 2021				
IXABEPILONE - IXEMPRA KIT							
N022065 002		RE41911	Sep 28, 2020	DS DP U-961			
		RE41911*PED	Mar 28, 2021				
KETOCONAZOLE - EXTINA							
N021738 001		8026238	Oct 19, 2018	DP U-1213			
LAMIVUDINE; ZIDOVUDINE - LAMIVUDINE AND ZIDOVUDINE							
A079081 001						PC	May 15, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N021880 001	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N021880 002	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N021880 003	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N021880 004	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N021880 005	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
LINAGLIPTIN - TRADJENTA						
N201280 001	>A> 8119648	Aug 12, 2023	U-774			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N201281 001	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	>A> 8119648	Aug 12, 2023	U-802			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N201281 002	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	>A> 8119648	Aug 12, 2023	U-802			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N201281 003	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	>A> 8119648	Aug 12, 2023	U-802			
LIRAGLUTIDE RECOMBINANT - VICTOZA						
N022341 001	8114833	Aug 13, 2025	DP			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 001	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 002	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 003	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 004	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7671030	Feb 24, 2023	DP U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687467	Apr 08, 2023	DP U-842			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 005	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 006	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LUBIPROSTONE - AMITIZA						
N021908 001	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022	U-1214			
	8114890	Sep 05, 2020	DP			
LUBIPROSTONE - AMITIZA						
N021908 002	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N202270 001	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N202270 002	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N202270 003	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE						
A078458 001					PC	Jul 01, 2012
METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE						
A078458 002					PC	Jul 01, 2012
METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE						
A078458 003					PC	Jul 01, 2012
MICONAZOLE - ORAVIG						
N022404 001	7651698	Sep 11, 2022	U-1051			
MIFEPRISTONE - KORLYM						
N202107 001					NP	Feb 17, 2015
MITOMYCIN - MITOSOL						
N022572 001	**>A>** 7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
MONTELUKAST SODIUM - SINGULAIR						
N020829 002					**>A>** NPP	Mar 26, 2015
MONTELUKAST SODIUM - SINGULAIR						
N020830 001					**>A>** NPP	Mar 26, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MONTELUKAST SODIUM - SINGULAIR							
N020830 002						**>A>** NPP	Mar 26, 2015
MONTELUKAST SODIUM - SINGULAIR							
N021409 001						**>A>** NPP	Mar 26, 2015
NAFTIFINE HYDROCHLORIDE - NAFTIN							
N019599 002						NS	Jan 13, 2015
NICOTINE - NICODERM CQ							
N020165 004		8075911	May 22, 2021	DP			
NICOTINE - NICODERM CQ							
N020165 005		8075911	May 22, 2021	DP			
NICOTINE - NICODERM CQ							
N020165 006		8075911	May 22, 2021	DP			
NITRIC OXIDE - INOMAX							
N020845 002		5558083	Nov 22, 2013	DP U-1226			
		5558083*PED	May 22, 2014				
		5732693	Dec 13, 2016	DP U-1230			
		5732693*PED	Jun 13, 2017				
		5752504	Dec 13, 2016	DP U-1230			
		5752504*PED	Jun 13, 2017				
NITRIC OXIDE - INOMAX							
N020845 003		5558083	Nov 22, 2013	DP U-1226			
		5558083*PED	May 22, 2014				
		5732693	Dec 13, 2016	DP U-1230			
		5732693*PED	Jun 13, 2017				
		5752504	Dec 13, 2016	DP U-1230			
		5752504*PED	Jun 13, 2017				
NITROGLYCERIN - NITROLINGUAL PUMPSPRAY							
N018705 002	**>A>**	7872049	Mar 14, 2028	DP U-39			
OXCARBAZEPINE - TRILEPTAL							
N021285 001		8119148	Dec 19, 2020	DP U-724			
		8119148*PED	Jun 19, 2021				
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N022272 001		8114383	Oct 10, 2024	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N022272 002		8114383	Oct 10, 2024	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N022272 003		8114383	Oct 10, 2024	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N022272 004		8114383	Oct 10, 2024	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N022272 005		8114383	Oct 10, 2024	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N201655 001	**>A>**	7851482	Jul 10, 2029	DS			
		8114383	Aug 08, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N201655 002	**>A>**	7851482	Jul 10, 2029	DS			
		8114383	Aug 08, 2024	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N201655 003	**>A>**	7851482	Jul 10, 2029	DS			
		8114383	Aug 08, 2024	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N201655 004	**>A>**	7851482	Jul 10, 2029	DS			
		8114383	Aug 08, 2024	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N201655 005	**>A>**	7851482	Jul 10, 2029	DS			
		8114383	Aug 08, 2024	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N201655 006	**>A>**	7851482	Jul 10, 2029	DS			
		8114383	Aug 08, 2024	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N201655 007	**>A>**	7851482	Jul 10, 2029	DS			
		8114383	Aug 08, 2024	DP			
PACLITAXEL - ABRAXANE							
N021660 001	**>A>**	8138229	Dec 09, 2023	DP U-1092			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA							
N022222 001						**>A>** NCE	Mar 01, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA							
N022222 002						**>A>** NCE	Mar 01, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA							
N022222 003						**>A>** NCE	Mar 01, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE							
N022542 001						**>A>** NCE	Mar 01, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE							
N022542 002						**>A>** NCE	Mar 01, 2017
PAZOPANIB HYDROCHLORIDE - VOTRIENT							
N022465 001		8114885	Dec 19, 2021	DS DP			
PAZOPANIB HYDROCHLORIDE - VOTRIENT							
N022465 002		8114885	Dec 19, 2021	DS DP			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N202799 001						**>A>** NCE	Mar 27, 2017
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N202799 002						**>A>** NCE	Mar 27, 2017
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N202799 003						**>A>** NCE	Mar 27, 2017
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N202799 004						**>A>** NCE	Mar 27, 2017
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N202799 005						**>A>** NCE	Mar 27, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N202799 006					**>A>** NCE	Mar 27, 2017
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 001	**>A>** 8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 002	**>A>** 8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 003	**>A>** 8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 004	**>A>** 8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N050750 001	**>A>** 8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N050750 002	**>A>** 8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N050750 003	**>A>** 8133883	Apr 14, 2023	DP U-282			
RALTEGRAVIR POTASSIUM - ISENTRESS						
N022145 001					**>A>** M-114	Mar 28, 2015
RALTEGRAVIR POTASSIUM - ISENTRESS						
N203045 001	7169780	Oct 03, 2023	DS DP		**>A>** M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
RALTEGRAVIR POTASSIUM - ISENTRESS						
N203045 002	7169780	Oct 03, 2023	DS DP		**>A>** M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
REGADENOSON - LEXISCAN						
N022161 001	8106029	Jun 22, 2019	U-1042			
	8106183	Feb 02, 2027	DS			
	>A> 8133879	Jun 22, 2019	DP			
RILPIVIRINE HYDROCHLORIDE - EDURANT						
N202022 001	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
ROTIGOTINE - NEUPRO						
N021829 001					**>A>** I-647	Apr 02, 2015
					>A> I-646	Apr 02, 2015
ROTIGOTINE - NEUPRO						
N021829 002					**>A>** I-647	Apr 02, 2015
					>A> I-646	Apr 02, 2015
ROTIGOTINE - NEUPRO						
N021829 003					**>A>** I-647	Apr 02, 2015
					>A> I-646	Apr 02, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SILDENAFIL CITRATE - REVATIO						
N021845 001	5250534	Mar 27, 2012	DS DP		I-598	May 07, 2012
	5250534*PED	Sep 27, 2012			PED	Nov 07, 2012
SILDENAFIL CITRATE - REVATIO						
N022473 001	5250534	Mar 27, 2012	DS DP		NDF	Nov 20, 2012
	5250534*PED	Sep 27, 2012			PED	May 20, 2013
SILDENAFIL CITRATE - VIAGRA						
N020895 001	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
SILDENAFIL CITRATE - VIAGRA						
N020895 002	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
SILDENAFIL CITRATE - VIAGRA						
N020895 003	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
SODIUM NITRITE - SODIUM NITRITE						
N203922 001					ODE	Jan 14, 2018
SODIUM THIOSULFATE - SODIUM THIOSULFATE						
N203923 001					ODE	Jan 14, 2018
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO						
N022239 001	8118771	Aug 10, 2023	DP			
TAFLUPROST - ZIOPTAN						
N202514 001	5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 001	8114383	Oct 10, 2024	DP			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 002	8114383	Oct 10, 2024	DP			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 003	8114383	Oct 10, 2024	DP			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 004	8114383	Oct 10, 2024	DP			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 005	8114383	Oct 10, 2024	DP			
TELAVANCIN HYDROCHLORIDE - VIBATIV						
N022110 001	8101575	May 01, 2021	DP			
TELAVANCIN HYDROCHLORIDE - VIBATIV						
N022110 002	8101575	May 01, 2021	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TELBIVUDINE - TYZEKA						
N022154 001	7858594	Sep 11, 2023	DS DP U-999			
TEMSIROLIMUS - TORISEL						
N022088 001	5362718	Apr 18, 2014	DS DP		M-92	Jul 09, 2013
	5362718*PED	Oct 18, 2014			M-91	Apr 26, 2013
	8026276	Jan 20, 2026	DP		NCE	May 30, 2012
	8026276*PED	Jul 20, 2026			ODE	May 30, 2014
					PED	Nov 30, 2014
					PED	Jan 09, 2014
					PED	Oct 26, 2013
					PED	Nov 30, 2012
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N021356 001					NPP	Jan 18, 2015
					PED	Jul 18, 2015
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N022577 001	5922695	Jul 25, 2017	DS U-250		NDF	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-256		PED	Jul 18, 2015
	5922695	Jul 25, 2017	DS U-999			
	5922695	Jul 25, 2017	DS U-248			
	5922695*PED	Jan 25, 2018				
	5935946	Jul 25, 2017	DP U-999	Y		
	5935946	Jul 25, 2017	DP U-248	Y		
	5935946	Jul 25, 2017	DP U-250	Y		
	5935946	Jul 25, 2017	DP U-256	Y		
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
TESTOSTERONE - TESTOSTERONE						
N202763 001					NP	Feb 14, 2015
TOPIRAMATE - TOPAMAX						
N020505 001					**>A>** NPP	Jul 15, 2014
TOPIRAMATE - TOPAMAX						
N020505 002					**>A>** NPP	Jul 15, 2014
TOPIRAMATE - TOPAMAX						
N020505 004					**>A>** NPP	Jul 15, 2014
TOPIRAMATE - TOPAMAX						
N020505 005					**>A>** NPP	Jul 15, 2014
TOPIRAMATE - TOPAMAX						
N020844 001					**>A>** NPP	Jul 15, 2014
TOPIRAMATE - TOPAMAX						
N020844 002					**>A>** NPP	Jul 15, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE						
A091607 001					PC	Jun 27, 2012
TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE						
A091607 002					PC	Jun 27, 2012
TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE						
A091607 003					PC	Jun 27, 2012
TRAZODONE HYDROCHLORIDE - OLEPTRO						
N022411 001	**>A>** 8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - OLEPTRO						
N022411 002	**>A>** 8133893	Mar 13, 2029	DS DP			
TRIAMCINOLONE ACETONIDE - TRIESENCE						
N022048 001	**>A>** 8128960	Dec 17, 2029	DP			
VISMODEGIB - ERIVEDGE						
N203388 001					NCE	Jan 30, 2017
VORINOSTAT - ZOLINZA						
N021991 001	8093295	May 16, 2026	DP			
	8101663	Mar 04, 2023	U-892			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm